Interferon and Its Inducers

  • P. B. Sehgal
  • L. M. Pfeffer
  • I. Tamm
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 61)

Abstract

Interferons are a group of inducible cellular proteins that interact with mammalian and other vertebrate cells and render them resistant to infection by a wide variety of RNA-containing or DNA-containing viruses. In addition to a marked antiviral effect, interferons cause numerous changes in the phenotype of target cells, including a reduction in the rate of cell proliferation and alterations in the structure and function of the cell surface, the distribution of cytoskeletal elements, and the expression of several differentiated cellular functions. The use of interferons and interferon inducers to treat human viral and neoplastic diseases is currently under intensive investigation. Considerable attention is thus focused on the structure and function of human interferons. Furthermore, investigations of the mechanisms which underlie the induction and the actions of interferons have led to novel insights into the regulation of gene expression in eukaryotic cells as well as into the pathophysiology of viral diseases. Thus, interferon research represents an important and rapidly advancing area of biomedical research today.

Keywords

Polypeptide Thymidine Colchicine Adriamycin Encephalomyelitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abreu SL, Bancroft FC (1978) Intracellular location of human fibroblast interferon messenger RNA. Biochem Biophys Res Commun 82: 1300–1305PubMedGoogle Scholar
  2. Abreu SL, Bancroft FC, Stewart WE II (1979) Interferon priming: effects on interferon messenger RNA. J Biol Chem 254: 4114–4118PubMedGoogle Scholar
  3. Adams A, Strander H, Cantell K (1975) The sensitivity of Epstein Barr virus transformed human lymphoid cells to interferon. J Gen Virol 28: 207–214PubMedGoogle Scholar
  4. Adolf GR, Swetly P (1979) Interferon production by human lymphoblastoid cells is stimulated by inducers of Friend cell differentiation. Virology 99: 158–166PubMedGoogle Scholar
  5. Anderson AO, Reynolds JA, Harrington DG Immunomodulating effect of polynucleotides on lymphocyte traffic and antiviral immunity Proceedings of Symposium on Potentiation of Immune Response to Vaccines. J. Infect. Dis. to be publishedGoogle Scholar
  6. Anfinsen CB, Bose S, Corley L, Gurari-Rotman D (1974) Partial purification of human interferon by affinity chromatography. Proc Natl Acad Sci USA 71: 3139–3142PubMedGoogle Scholar
  7. Ankel HC, Chany B, Galliot B, Chevalier MJ, Robert M (1973) Antiviral effect on interferon covalently bound to sepharose. Proc Natl Acad Sci USA 70: 2360–2363PubMedGoogle Scholar
  8. Aoki FY, Reed SE, Craig JW, Tyrrell DAJ, Lees LJ (1978) Effect of polynucleotide interferon inducer of fungal origin on experimental rhinovirus infection in humans. J. Infect. Dis. 137: 82–86PubMedGoogle Scholar
  9. Arnaoudova V (1976) Treatment and prevention of acute respiratory virus infections in children with leukocytic interferon (Abstr.). Virologie (Bucuresti) 27: 83–88Google Scholar
  10. Arvin AM, Yeager AS, Merigan TC (1976) Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants. J Infect Dis 133 (Suppl): A205 — A210PubMedGoogle Scholar
  11. Arvin AM, Feldman S, Merigan TC (1978) Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Antimicrob Agents Chemother 13: 605–607PubMedGoogle Scholar
  12. Atanasiu P, Chany C (1960) Action d’un interféron provenant de cellules malignes sur l’infection expérimentale du hamster nouveau-né par le virus du polyome. C R Acad Sci (Paris) 251: 1687–1689Google Scholar
  13. Atherton KT, Burke DC (1975) Interferon induction by viruses and polynucleotides: a differential effect of camptothecin. J. Gen. Virol. 29: 297–304PubMedGoogle Scholar
  14. Atherton KT, Burke DC (1978) The effects of some different metabolic inhibitors on interferon superinduction. J Gen Virol 41: 229–237PubMedGoogle Scholar
  15. Atkins GJ, Lancashire CL (1976) The induction of interferon by temperature-sensitive mutants of Sindbis virus: its relationship to double-stranded RNA synthesis and cytopathic effect. J Gen Virol 30: 157–161PubMedGoogle Scholar
  16. Atkins GJ, Johnston MD, Westmacott LM, Burke DC (1974) Induction of interferon in chick cells by temperature-sensitive mutants of Sindbis virus. J Gen Virol 25: 381–384PubMedGoogle Scholar
  17. Azuma M, Svenaga T, Yoshida I, Mizuno F (1978) Interferon synthesis in human diploid cells pretreated with insulin. Antimicrob Agents and Chemother 13: 566–569Google Scholar
  18. Bachner L, Declercq E, Thang MN (1975) Sepharose-bound poly(I) poly(C): interaction with cells and interferon production. Biochem Biophys Res Commun 63: 476–47PubMedGoogle Scholar
  19. Baer GM, Shaddock JH, Moore SA, Yager PA, Baron SS, Levy HB (1977) Successful prophylaxis against rabies in mice and rhesus monkeys: the interferon system and vaccine. J Infect Dis 136: 286–291PubMedGoogle Scholar
  20. Baglioni C (1979) Interferon-induced enzymatic activities and their role in the antiviral state. Cell 17: 255–264PubMedGoogle Scholar
  21. Baglioni C, Lenz JR, Maroney PA (1978a) The effect of salt concentration on the inhibition of protein synthesis by double-stranded RNA. Eur J Biochem 92:157–163Google Scholar
  22. Baglioni C, Minks MA, Maroney PA (1978b) Interferon action may be mediated by activation of a nuclease by pppA2’p5’A2’A. Nature 273:684–687Google Scholar
  23. Baglioni C, Maroney PA, West DK (1979) 2’S’oligo(A) polymerase activity and inhibition of viral RNA synthesis in interferon treated HeLA cells. Biochemistry 18:1765–1770Google Scholar
  24. Bailey DW (1971) Recombinant-inbred strains. An aid to finding identity, linkage, and function of histocompatibility and other genes. Transplantation 11: 325–327PubMedGoogle Scholar
  25. Baker PN, Bradshaw TK, Morser J, Burke DC (1979) The effect of 5-bromodeoxyuridine on interferon production in human cells. J Gen Virol 45: 177–184PubMedGoogle Scholar
  26. Balkwill F, Taylor-Papadimitriou J (1978) Interferon affects both G1 and S + G2 in cells stimulated from quiescence to growth. Nature 274: 798–800PubMedGoogle Scholar
  27. Balkwill FR, Watling D, Taylor-Papadimitriou J (1979) The effect of interferon on cell growth and the cell cycle. In: Chandra P (ed) Antiviral mechanisms in the control of neoplasia. Plenum Press, NY, pp 712–728Google Scholar
  28. Ball LA Induction, purification and properties of 2’S’ oligoadenylate synthetase. In: Koch G & Richter D (eds) Regulation of macromolecular synthesis by low molecular weight mediators. Academic PressGoogle Scholar
  29. Ball LA, White CN (1978) Oligonucleotide inhibitor of protein synthesis made in extracts of interferon treated chick embryo cells: comparison with the mouse low molecular weight inhibitor. Proc Natl Acad Sci USA 75: 1167–1171PubMedGoogle Scholar
  30. Barmak SL, Vilcek J (1973) Altered cellular responses to interferon induction by poly(I)–poly(C): priming and hyporesponsiveness in cells treated with interferon preparations. Arch Virology 43: 273–283Google Scholar
  31. Baron S, Buckler CE, McCloskey RV, Kirschstein RL ( 1966 a) Role of interferon during viremia. I. Production of circulating interferon. J Immunol 96: 12–17PubMedGoogle Scholar
  32. Baron S, Buckler CE, Friedman RM, McCloskey RV (1966b) Role of interferon during viremia. II. Protective action of circulating interferon. J Immunol 96: 17–24PubMedGoogle Scholar
  33. Bart RS, Porzio NR, Kopf AW, Vilcek JT, Cheng EH, Farcet Y (1980) Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Research 40:614–619Google Scholar
  34. Bausek GH, Merigan TC (1969) Cell interaction with a synthetic polynucleotide and interferon production in vitro. Virology 39: 491–498PubMedGoogle Scholar
  35. Baxt B, Sonnabend JA, Bablanian R (1977) Effects of interferon on vesicular stomatitis virus transcription and translation. J Gen Virol 35: 325–334PubMedGoogle Scholar
  36. Bekesi JG, Roboz JP, Zimmerman E, Holland JF (1976) Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy or interferon. Cancer Res 36: 631–636PubMedGoogle Scholar
  37. Berger SL, Hitchcock MJM, Zoon KC, Birkenmeier CS, Friedman RM, Chang EH (1980) Characterization of interferon messenger RNA synthesis in Namalva cells. J Biol Chem 255: 2955–2961PubMedGoogle Scholar
  38. Berman B, Vilcek J (1974) Cellular binding characteristics of human interferon. Virology 57: 378–386PubMedGoogle Scholar
  39. Berman LD (1970) Inhibition of oncogenicity of murine sarcoma virus (Harvey) in mice by interferon. Nature 227: 1349–1350PubMedGoogle Scholar
  40. Berthold W, Tan C, Tan YH (1978) Purification and in vitro labeling of interferon from a human fibroblastoid cell line. J Biol Chem 253: 5206–5212PubMedGoogle Scholar
  41. Besancon F, Ankel H (1974 a) Inhibition of interferon action by plant lectins. Nature 250:784–786Google Scholar
  42. Besancon F, Ankel H (1974b) Binding of interferon to gangliosides. Nature 252: 478–480PubMedGoogle Scholar
  43. Besancon F, Ankel H (1976) Inhibition de l’action de l’interféron par des hormones glycoprotéiques. CR Acad Sci (Paris) 283: 1807–1810Google Scholar
  44. Bialy HS, Colby S (1972) Inhibition of early vaccinia virus ribonucleic acid synthesis in interferon-treated chicken embryo fibroblasts. J Virol 9: 286–289PubMedGoogle Scholar
  45. Billiau A (1970) The refractory state after induction of interferon with double-stranded RNA. J Gen Virol 7: 225–232PubMedGoogle Scholar
  46. Billiau A, Joniau M, De Somer P (1973 a) Mass production of human interferon in diploid cells stimulated by poly(I) poly(C). J Gen Virol 19:1–8Google Scholar
  47. Billiau A, Sobis M, De Somer P (1973 b) Influence of interferon on virus particle formation in different oncornavirus carrier cell lines. Int J Cancer 12:646–653Google Scholar
  48. Billiau A, Edy VG, De Clercq E, Heremans H, De Somer P (1975) Influence of interferon on the synthesis of virus particle in oncornavirus carrier cell lines. III. Survey of effects on A-, B-, and C-type oncornaviruses. Int J Cancer 15: 947–950PubMedGoogle Scholar
  49. Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades J, De Somer P (1977) Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother 12: 11–15PubMedGoogle Scholar
  50. Billiau A, Edy V, De Somer P (1978) The clinical use of fibroblast interferon. In: Chandra P (ed) Antiviral Mechanisms in the Control of Neoplasia. Plenum Press, NY pp 675–696Google Scholar
  51. Billiau A, Van Damme J, Van Leuven F, Edy VG, De Ley M, Cassiman J-J, Van Den Berg-he H, De Somer P (1979 a) Human fibroblast interferon for clinical trials: production, partial-purification, and characterization. Antimicrob Agents Chemother 16:49–55Google Scholar
  52. Billiau A, De Somer P, Edy VG, De Clercq E, Heremans H (1979 b) Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans. Antimicrob Agents Chemother 16:56–63Google Scholar
  53. Blaineau C, Kishida T, Salle M, Peries J (1975) Inhibitory effect of interferon preparation on the induction of endogenous mouse type C virus by iododeoxyuridine. IRGS Med Sci 3: 258–263Google Scholar
  54. Blalock JE, Gifford GE (1976) Suppression of interferon production by vitamin A. J Gen Virol 32: 143–146PubMedGoogle Scholar
  55. Blalock J, Stanton JD (1980) Common pathways of interferon and hormonal action. Nature 283: 406–408PubMedGoogle Scholar
  56. Blomgren H, Cantell K, Johansson B, Lagergren C, Ringborg U, Strander H (1976) Interferon therapy in Hodgkin’s disease. Acta Med Scand 199: 527–532PubMedGoogle Scholar
  57. Bocci V, Pacini A, Pessina GP, Bargigli V, Russi M (1977) Metabolism of interferon: hepatic clearance of natural and desialylated interferon. J Gen Virol 35: 525–526PubMedGoogle Scholar
  58. Bodo G, Scheirer W, Suh M, Schultze B, Morak I, Jangwirth C (1972) Protein synthesis in pox-virus infected cells treated with interferon. Virology 50: 140–147PubMedGoogle Scholar
  59. Booth BW, Borden EC (1978) Increase by calcium in production of poly rI poly rC induced interferon by L929 cells. J Gen Virol 40: 485–488PubMedGoogle Scholar
  60. Borden EC, Murphy FA (1971) The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol 106: 134–138PubMedGoogle Scholar
  61. Borden EC, Booth BW, Leonhardt PH (1978) Mechanistic studies of polyene enhancement of interferon production by poly(I) • poly(C). Antimicrob Agents Chemother 13: 159–164PubMedGoogle Scholar
  62. Borden E, Dao T, Holland J, Gutterman J, Merigan T (1980) Interferon in recurrent breast carcinoma: preliminary report of the American Cancer Society Clinical Trials Program. Interferon Sci Memoranda I-A896, p 10Google Scholar
  63. Bose S, Gurari-Rotman D, Ruegg U.Th, Corley L, Anfinsen CB (1976) Apparent dispensability of the carbohydrate moiety of human interferon for antiviral activity. J Biol Chem 251: 1659–1662PubMedGoogle Scholar
  64. Bourgeade MF, Chany C (1976) Inhibition of interferon action by cytochalasin B, colchicine and vinblastine. Proc Soc Exp Biol Med 153: 486–488Google Scholar
  65. Bradley EC, Ruscetti FW (1981) Effect of fibroblast, lymphoid, and myeloid interferons on human tumor colony formation in vitro. Cancer Res 41: 244–249PubMedGoogle Scholar
  66. Braun W, Levy HB (1972) Interferon preparations as modifiers of immune responses. Proc Soc Exp Biol Med 141: 769–773PubMedGoogle Scholar
  67. Breinig MC, Armstrong JA, Ho M (1975) Rapid onset of hyporesponsiveness to interferon induction on reexposure to polyribonucleotide. J Gen Virol 26: 149–158PubMedGoogle Scholar
  68. Bridgen PJ, Anfinsen CB, Corley L, Bose S, Zoon KC, Ruegg VT, Buckler CE (1977) Human lymphoblastoid interferon: large scale production and partial purification. J Biol Chem 252: 6585–6587PubMedGoogle Scholar
  69. Brodeur BR, Merigan TC (1974) Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. J Immunol 113: 1319–1325PubMedGoogle Scholar
  70. Brouty-Boyé D, Tovey MG (1977) Inhibition by interferon of thymidine uptake in chemostat cultures of L1210 cells. Intervirology 9: 243–252Google Scholar
  71. Brouty-Boyé D, Zetter BR (1980) Inhibition of cell motility by interferon. Science 208:516–518Google Scholar
  72. Brouty-Boyé D, Macieira-Coehlo A, Fiszman M, Gresser I (1973) Effect of interferon on macromolecular synthesis in L1210 cells in vitro. Int J Cancer 12: 250–258PubMedGoogle Scholar
  73. Brown GE, Lebleu B, Kawakita M,Shaila S, Sen GC, Lengyel P (1976) Increased endonuclease activity in an extract from mouse Ehrlich ascites tumor cells which had been treated with a partially purified interferon preparation: dependence on double-stranded RNA. Biochem Biophys Res Commun 69: 114–122PubMedGoogle Scholar
  74. Burke DC, Buchan A (1965) Interferon production in chick embryo cells. I. Production by ultraviolet-inactivated virus. Virology 26: 28–35PubMedGoogle Scholar
  75. Burke DC, Graham CF, Lehman JM (1978) Appearance of interferon inducibility and sensitivity during differentiation of murine teratocarcinoma cells in vitro. Cell 13: 243–248PubMedGoogle Scholar
  76. Cabrer B, Taira H, Broeze RJ, Kempe TD, Williams K, Slattery E, Konigsberg WH, Lengyel P (1979) Structural characteristics of interferons from mouse Ehrlich ascites tumor cells. J Biol Chem 254: 3681–3684PubMedGoogle Scholar
  77. Came PE, Moore DH (1971) Inhibition of spontaneous mammary carcinoma of mice by treatment with interferon and poly I C. Proc Soc Exp Biol Med 137: 304–305PubMedGoogle Scholar
  78. Came PE, Moore DH (1972) Effect of exogenous interferon treatment on mouse mammary tumors. J Natl Cancer Inst 48: 1151–1154PubMedGoogle Scholar
  79. Came PE, Schafer TW, Silver GH (1976) Sensitivity of rhinoviruses to human leucocyte and fibroblast interferons. J Infect Dis [Suppl] 133: A136 - A138Google Scholar
  80. Cantell K (1979) Why is interferon not in clinical use today? Interferon 1: 1–28Google Scholar
  81. Cantell K, Hirvonen S (1977) Preparation of human leukocyte interferon for clinical use. In: Baron S, Dianzani F (eds) The interferon system: a current review. Tex Rep Biol Med 35: 138–141Google Scholar
  82. Cantell K, Hirvonen S (1978) Large-scale production of human leukocyte interferon containing 108 units per ml. J Gen Virol 39: 541–543PubMedGoogle Scholar
  83. Cantell K, Paucker K (1963) Quantitative studies on viral interference in suspended L cells. IV. Production and assay of interferon. Virology 21: 11–21PubMedGoogle Scholar
  84. Cantell K, Pyhala L (1973) Circulating interferon in rabbits after administration of human interferon by different routes. J Gen Virol 20: 97–104PubMedGoogle Scholar
  85. Cantell K, Hirvonen S, Mogensen KE, Pyhala L (1974) Human leukocyte interferons: production, purification, stability and animal experiments. The production and use of interferon for the treatment of human virus infections. In: Waymouth C (ed) In Vitro Monograph 3: 35–38Google Scholar
  86. Cantell K, Ehnholm G, Mattila K, Kostiainen E (1980) Interferon and high-density lipoproteins. New Engl J Med 302: 1032–1033PubMedGoogle Scholar
  87. Cantor H, Asofsky R, Levy HB (1970) The effect of polyinosinic polyadenylic acid upon graft vs host activity in BALB/C mice. J Immunol 104: 1035PubMedGoogle Scholar
  88. Carter WA, Horoszewicz JS (1978) Human interferon and its inducers: clinical program overview at Roswell Park Memorial Institute. Cancer Treat Rep 62: 1897–1898PubMedGoogle Scholar
  89. Carter WA, Pitha PM, Marshall LW, Tazawa I, Tazawa S, Ts’o POP (1972) Structural requirements of then I rC complex for induction of human interferon. J Mol Biol 70: 567–575PubMedGoogle Scholar
  90. Cavalieri RL, Havell EA, Pestka S, Vilcék J (1977 a) Synthesis of human interferon by Xeno-pus laevis oocytes: two structural genes for interferons in human cells. Proc Natl Acad Sci USA 74:3287–3291Google Scholar
  91. Cavalieri RL, Havell EA, Vilcék J, Pestka S (1977 b) Induction and decay of human fibroblast interferon messenger RNA. Proc Natl Acad Sci USA 74:4415–4419Google Scholar
  92. Cerrotini JC, Brunner KT, Lindahl P, Gresser I (1973) Inhibitory effect of interferon preparations and inducers on the multiplication of transplanted allogenic spleen cells and syngenic bone marrow cells. Nature 242: 152–153Google Scholar
  93. Chang EH, Mims SJ, Triche TJ, Friedman RM (1977) Interferon inhibits mouse leukemia virus release: an electron microscopic study. J gen Virol 34: 363–371PubMedGoogle Scholar
  94. Chang EH, Jay FT, Friedman RM (1978) Physical morphological, and biochemical alterations in the membrane of AKR mouse cells after interferon treatment. Proc Natl Acad Sci USA 75: 1859–1863PubMedGoogle Scholar
  95. Chany C (1976) Membrane-bound interferon specific cell receptor system: role in the establishment and amplification of the antiviral state. Biomedicine 24: 148–160PubMedGoogle Scholar
  96. Chany C, Cerutti I (1977) Enhancement of antiviral protection against encephalomyocarditis virus by a combination of isoprinosine and interferon. Arch Virol 55: 225–232PubMedGoogle Scholar
  97. Chany C, Ankel H, Bourgeade MF (1975) Interferon cell receptor interactions. In: Pollard M (ed) Perspectices in virology, Vol 9. Academic Press, NY, p 269Google Scholar
  98. Chany C, Rousset S, Bourgeade MF, Mathieu D, Grégoire A (1980) Role of receptors and cytoskeleton in reverse transformation and steroidogenesis induced by interferon. In: Ann NY Acad Sci 350: 254–265Google Scholar
  99. Cheeseman SH, Rubin RH, Stewart JA, Tolkoff-Rubin NE, Cosimi AD, Cantell K, Gilbert J, Winkle S, Herrin JT, Black PH, Russell PS, Hirsch MS (1979) Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med 300: 1345–1349Google Scholar
  100. Clemens MJ, Williams BRG (1978) Inhibition of cell free protein synthesis by pppA2-p5’A2’_ p5’A: a novel oligonucleotide synthesized by interferon treated L cell extracts. Cell 13:565–572Google Scholar
  101. Content J, Lebleu B, Nudel U, Zilberstein A, Berissi H, Revel M (1975) Blocks on elongation and initiation of protein synthesis induced by interferon treatment in mouse L cells. Eur J Biochem 54:1–10Google Scholar
  102. Cho Y, Tanamoto K-I, Oh Y, Homma JY (1979) Differences of chemical structures of Pseudomonas aeruginosa lipopolysaccharide essential for adjuvanticity and antitumor and interferon-inducing activities. FEBS Letters 105: 120–122PubMedGoogle Scholar
  103. Clemens MJ, Williams BRG (1978) Inhibition of cell free protein synthesis by pppA2-p5’A2’_ p5’A: a novel oligonucleotide synthesized by interferon treated L cell extracts. Cell 13: 565–572PubMedGoogle Scholar
  104. Content J, Lebleu B, Nudel U, Zilberstein A, Berissi H, Revel M (1975) Blocks on elongation and initiation of protein synthesis induced by interferon treatment in mouse L cells. Eur J Biochem 54: 1–10PubMedGoogle Scholar
  105. Content J, Lebleu B, De Clercq E (1978) Differential effects of various double-stranded RNAs on protein synthesis in rabbit reticulocyte lysates. Biochemistry 17: 88–94PubMedGoogle Scholar
  106. Coster DJ, Falcon MG, Cantell K, Jones BR (1977) Clinical experience of human leucocyte interferon in the management of herpetic keratitis. Trans Ophthalmol Soc UK 97:327–329Google Scholar
  107. Creasey AA, Bartholomew JC, Merigan TC (1980) Role of Go—G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 77: 1471–1475PubMedGoogle Scholar
  108. Dahl H, Degre M (1976) The effect of ascorbic acid on production of human interferon and antiviral activity in vitro. Acta Pathol Microbiol Scand B84: 280–285Google Scholar
  109. Davey MW, Huang JW, Sulkowski E, Carter WA (1975) Hydrophobic binding sites on human interferon. J Biol Chem 250: 348–356PubMedGoogle Scholar
  110. Davey MW, Sulkowski E, Carter WA (1976) Binding of human fibroblast interferon to concanavalin A-agarose. Involvement of carbohydrate recognition and hydrophobic interaction. Biochem 15: 704–710Google Scholar
  111. DeClercq E (1974) Synthetic interferon inducers. In: Topics in current chemistry 52. Springer, Berlin Heidelberg New York, p 173Google Scholar
  112. DeClercq E (1977) Polynucleotides as inducers of interferon. In: Walton AG (ed) Proceedings of the first Cleveland symposium on macromolecules. Elsevier, Amsterdam, Oxford, NY, pp 217–243Google Scholar
  113. DeClercq E (1980) Interferon inducers. Antibiotics Chemother 27: 251–287Google Scholar
  114. DeClercq E, De Somer P (1971) Role of interferon in the protective effect of the double-stranded polyribonucleotide against murine tumors induced by moloney sarcoma virus. J Natl Cancer Inst 47: 1345–1355Google Scholar
  115. DeClercq E, Merigan TC (1971) Moloney sarcoma virus-induced tumors in mice: inhibition or stimulation by (poly-I) • (poly-C). Proc Soc Exp Biol Med 137: 590–594Google Scholar
  116. DeClercq E, Edy VG, Cassiman JJ (1975) Nonantiviral activities of interferon are not controlled by chromosome 21. Nature 256: 132–134Google Scholar
  117. DeClercq E, Edy VG, Cassiman JJ (1976) Chromosome 21 does not code for an interferon receptor. Nature 264: 249–251Google Scholar
  118. DeClercq E, Stollar BD, Thang MN (1978) Interferon inducing activity of polyinosinic acid. J Gen Virol 40: 203–212Google Scholar
  119. De Maeyer E, De Maeyer-Guignard J (1977) Effect of interferon on cell-mediated immunity. Tex Rep Biol Med 35: 370–374PubMedGoogle Scholar
  120. De Maeyer E, De Maeyer-Guignard J (1979 a) Interferons. Comprehensive Virology 15:205–284Google Scholar
  121. De Maeyer E, De Maeyer-Guignard J (1979 b) Considerations on mouse genes influencing interferon production and action. Interferon 1:75–100Google Scholar
  122. De Maeyer E, Hoyez MC, De Maeyer-Guignard J, Bailey DW (1979) Effect of mouse genotype on interferon production. III. Expression of If-1 by peritoneal macrophages in vitro. Immunogenetics 8: 257–263Google Scholar
  123. De Maeyer-Guignard J, De Maeyer E, Montagnier L (1972) Interferon messenger RNA: Translation in heterologous cells. Proc Natl Acad Sci USA 69: 1203–1207PubMedGoogle Scholar
  124. De Maeyer-Guignard J, Tovey MA, Gresser I, De Maeyer E (1978) Purification of mouse interferon by sequential affinity chromatography on poly(U)- and antibody-agarose columns. Nature 271: 622–625PubMedGoogle Scholar
  125. Derynck R, Content J, DeClercq E, Volckaest G, Tavernier J, Devos R, Fiers W (1980) Isolation and structure of a human fibroblast interferon gene. Nature 285: 542–547PubMedGoogle Scholar
  126. Desmyter J, Stewart WE II (1976) Molecular modification of interferon: attainment of human interferon in a conformation active on cat cells but inactive on human cells. Virology 70: 451–458PubMedGoogle Scholar
  127. Desmyter J, Ray MB, De Groote J, Bradburne AF, Desmet VJ, Edy VG, Billiau A, De Somer P, Mortelmans J (1976) Administration of human fibroblast interferon in chronic hepatitis B infection. Lancet 2: 645–647PubMedGoogle Scholar
  128. De Somer PA, Prinzie P, Denys P Jr, Schonne E (1962) Mechanism of action of interferon. I. Relationship with viral ribonucleic acid. Virology 16: 63–70Google Scholar
  129. De Somer P, Edy VG, Billiau A (1977) Interferon induced skin reactivity in man. Lancet 1: 47–48Google Scholar
  130. Desrosiers RC, Lengyel P (1977) Impairment of reovirus mRNA cap methylation in interferon treated L cells. Fed Proc 36: 812Google Scholar
  131. D’Hooghe CM, Brouty-Boyé D, Malaise EF, Gresser I (1977) Interferon and cell division. XII. Prolongation by interferon of the intermitotic time of mouse mammary tumor cells in vitro. Microcinematographic analysis. Exptl Cell Res 105: 73–76Google Scholar
  132. Dianzani F, Baron S (1977) The continued presence of interferon is not required for activation of cells by interferon. Proc Soc Exp Biol Med 155: 562–566PubMedGoogle Scholar
  133. Dianzani F, Cantagalli P, Gagnoni S, Rita G (1968) Effects of DEAE-dextran on production of interferon induced by synthetic double-stranded RNA in L cell cultures. Proc Soc Exp Biol Med 128: 708–710PubMedGoogle Scholar
  134. Dianzani F, Levy HB, Berg S, Baron S (1976) Kinetics of the rapid action of interferon. Proc Soc Exp Biol Med 152: 593–596PubMedGoogle Scholar
  135. Djeu JY, Heinbaugh JA, Holden HT, Herberman RB (1979) Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol 122:175–181Google Scholar
  136. Dolen JG, Carter WA, Horoszewics JS, Vladutiu AP, Leibowitz A, Nolan JP (1979) Fibroblast interferon treatment of a patient with chronic active hepatitis. Am J Med 67: 127–131PubMedGoogle Scholar
  137. Donahoe RM, Huang KY (1976) Interferon preparations enhance phagocytosis in vivo. Infect Immun 13: 1250–1253PubMedGoogle Scholar
  138. Dorner F, Scriba M, Weil R (1973) Interferon: evidence for its glycoprotein nature. Proc Natl Accad Sci USA 70: 1981–1985Google Scholar
  139. Douglas RG Jr, Waldman RH, Betts RF, Ganguly R (1979) Lack of effect of an interferon inducer, N,N-dihexadecyl-m-xylyenediamine, on rhinovirus challenge in humans. Antimicrob Agent Chemother 15: 269–272Google Scholar
  140. Dunnick JK, Galasso GJ (1979) Clinical trials with exogenous interferon: summary of a meeting. J Infect Dis 139: 109–123PubMedGoogle Scholar
  141. Edy VG, Billiau A Desomer P (1973) Enhancement of interferon production in mouse cell line: a high-yielding source of mouse interferon. Appld Microbiol 26: 434–436Google Scholar
  142. Edy VG, Braude IA, DeClercq E, Billiau A, Desomer P (1976) Purification of human fibroblast interferon by glass. J Gen Virol 33: 517–521PubMedGoogle Scholar
  143. Edy VG, Billiau A, Desomer P (1977) Purification of human fibroblast interferon by zinc chelate affinity chromatography. J Biol Chem 252: 5934–5936PubMedGoogle Scholar
  144. Edy VG, Billiau A, De Somer P (1978) Non-appearance of injected fibroblast interferon in circulation. Lancet 1: 451–452PubMedGoogle Scholar
  145. Einhorn S, Strander H Interferon therapy for neoplastic diseases in man: in vitro and in vivo studies. In: Stinebring W (ed) Production of human interferon and investigation of its clinical use. Proceedings of a workshop, Tissue Culture Association. Plenum Press, NY, to be publishedGoogle Scholar
  146. Emödi G, Just M (1974) Impaired interferon responses of children with congenital cytomegalovirus disease. Acta Paediatr Scand 63: 183–187PubMedGoogle Scholar
  147. Emödi G, Rufli T, Just M, Hernandez R (1975) Human interferon therapy for herpes zoster in adults. Scand J Infect Dis 7: 1–5PubMedGoogle Scholar
  148. Emödi G, O’Reilly R, Muller A, Everson LK, Binswanger U, Just M (1976) Effect of human exogenous leukocyte interferon in cytomegalovirus infections. J Infect Dis [Suppl] 133: A199 - A204Google Scholar
  149. Emond RTD, Evans B, Bowen ETW, Lloyd G (1977) A case of Ebola virus infections. Brit Med J 2: 541–544PubMedGoogle Scholar
  150. Eppstein DA, Samuel CE (1978) Mechanism of interferon action. Properties of an inter- feron mediated ribonucleic activity from mouse L929 cells. Virology 89: 240–251PubMedGoogle Scholar
  151. Epstein LB, Epstein CJ (1976) Localization of the gene AVG for the antiviral expression of immune and classical interferon to the distal portion of the long arm of chromosome 21. J Infect Dis 133: A56 - A62PubMedGoogle Scholar
  152. Falcoff E, Falcoff R, Lebleu B, Revel M (1973) Correlation between the antiviral effect of interferon treatment and the inhibition of in vitro mRNA translation in noninfected L cells. J Virol 12: 421–430PubMedGoogle Scholar
  153. Falcoff R, Sanceau J, Aujean O, Vaquero C (1980) Recovery by interferon of mengovirus induced shutoff of host protein synthesis. In: Vilcek J (ed) Conference on regulatory functions of interferons. NY Acad Sci, pp 522–532Google Scholar
  154. Farrell PJ, Balkow K, Hunt T, Jackson R (1977) Phosphorylation of initiation factor eIF-2 and the control of reticulocyte protein synthesis. Cell 11: 187–200PubMedGoogle Scholar
  155. Farrell PJ, Sen GC, Dubois MF, Ratner L, Slattery E, Lengyel P (1978) Interferon action: two distinct pathways for the inhibition of protein synthesis by double stranded RNA. Proc Natl Acad Sci 75: 5893–5897PubMedGoogle Scholar
  156. Farrell PJ, Broeze RJ, Lengyel P (1979) Accumulation of mRNA and protein in interferon-treated Ehrlich ascites tumor cells. Nature 279: 523–525PubMedGoogle Scholar
  157. Fast PE, Stringfellow DA (1980) Immune modulation by two antiviral isocytosines with different abilities to induce interferon. In: Nelson JD, Grassi C (eds) Current chemotherapy and infections diseases. Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, vol II. The American Society for Microbiology, Washington DC, pp 1396–1398Google Scholar
  158. Feingold DS, Keleti G, Youngner JS (1976) Antiviral activity of Brucella abortus preparations: separation of active components. Infection and Immunity 13: 763–767PubMedGoogle Scholar
  159. Fernandes MY, Wiktor TJ, Koprowski H (1964) Endosymbiotic relationship between animal viruses and host cells. J Exp Med 120: 1099–1116PubMedGoogle Scholar
  160. Field AK, Tytell AA, Lampson GP, Hilleman MR (1967) Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA 58: 1004–1009PubMedGoogle Scholar
  161. Findlay GM, MacCallum FO (1937) An interference phenomenon in relation to yellow fever and other viruses. J Path Bact 44: 405–424Google Scholar
  162. Finkelstein MS, Bausek GM, Merigan TC (1968) Interferon inducers in vitro: difference in sensitivity to inhibitors of RNA and protein synthesis. Science 161: 465–468PubMedGoogle Scholar
  163. Finter NB (1964) Protection of mice by interferon against systemic virus infections. Brit Med J 2: 981–985PubMedGoogle Scholar
  164. Finter NB (1967) Interferon in mice: protection against small doses of virus. J Gen Virol 1: 395–397PubMedGoogle Scholar
  165. Finter NB (1973) Interferons. North Holland Publ Co, AmsterdamGoogle Scholar
  166. Finter NB, Bridgen D (1978) The large scale production of human interferons and their possible uses in medicine. Trends in Bioch Sc 3: 76–80Google Scholar
  167. Frankfort HM, Havell EA, Croce CM, Vilcek JV (1978) The synthesis and actions of mouse and human interferons in mouse-human hybrid cells. Virology 89: 45–52PubMedGoogle Scholar
  168. Frayssinet C, Gresser I, Tovey M, Lindahl P (1973) Inhibitory effect of potent interferon preparations on the regenerations of mouse liver after partial hepatectomy. Nature 245: 146–147PubMedGoogle Scholar
  169. Frey TK, Jones EV, Cardamone JJ Jr, Youngner JS (1979) Induction of interferon in L cells by defective-interfering (DI) particles of vesicular stomatitis virus: lack of correlation with content of [±] snapback RNA. Virology 99: 95–102PubMedGoogle Scholar
  170. Friedman RM (1967) Interferon binding: the first step in establishment of antiviral activity. Science 156: 1760–1761PubMedGoogle Scholar
  171. Friedman RM (1968) Interferon inhibition of arbovirus protein synthesis. J Virol 2: 1081–1085PubMedGoogle Scholar
  172. Friedman RM (1977) Antiviral activity of interferon. Bacter Rev 41: 543–567Google Scholar
  173. Friedman RM (1979) Interferons: interactions with cell surfaces. Interferon 1: 53–74Google Scholar
  174. Friedman RM, Kohn L (1976) Cholera toxin inhibits interferon action. Biochem Biophys Res Commun 70: 1078–1081PubMedGoogle Scholar
  175. Friedman RM, Pastan I (1969) Interferon and cyclic 3’S’ adenosine monophosphate potentiation of antiviral activity. Biochem Biophys Res Commun 36: 735–739PubMedGoogle Scholar
  176. Friedman RM, Ramseur JM (1974) Inhibition of murine leukemia virus production in chronically infected AKR cells: a novel effect of interferon. Proc Natl Acad Sci USA 71: 3542–3544PubMedGoogle Scholar
  177. Friedman RM, Sonnabend JA (1965) Inhibition of interferon action by puromycin. J Immunology 95: 696–703Google Scholar
  178. Friedman RM, Chang EH, Ramseur JM, Myer MW (1975) Interferon-directed inhibition of chronic murine leukemia virus production in cell cultures: lack of effect on intracellular viral markers. J Virol 16: 569–574PubMedGoogle Scholar
  179. Fujisawa J, Iwakura Y, Kawade Y (1978) Nonglycosylated mouse L cell interferon produced by the action of tunicamycin. J Biol Chem 253: 8677–8679PubMedGoogle Scholar
  180. Fujita T, Saito S, Kohno S (1979) Priming increases the amount of interferon mRNA in poly(rI) • poly(rC)-treated L cells. J Gen Virol 45: 301–308PubMedGoogle Scholar
  181. Fulton F, Armitage P (1951) Surviving tissue suspensions for influenza virus titration. J Hyg Camb 49: 247–262PubMedGoogle Scholar
  182. Fuse A, Kuwata T (1976) Effects of interferon on the human clonal cell line, RSa. J Gen Virol 33: 17–22Google Scholar
  183. Gallien-Lartigue O, Carrez D, De Maeyer E, De Maeyer-Guignard J (1980) Strain dependence of the antiproliferative action of interferon on murine erhthroid precursors. Science 209: 292–293PubMedGoogle Scholar
  184. Galster RL, Lengyel P (1976) Formation and characteristics of reovirus subvirus particles in interferon-treated mouse L cells. Nucl Acids Res 3: 581–598PubMedGoogle Scholar
  185. Gandhi SS, Burke DC (1970) Interferon production by myxoviruses in chick embryo cells. J Gen Virol 6: 95–104PubMedGoogle Scholar
  186. Gardner LJ, Vilcek J (1979) Initial interaction of human fibroblast and leukocyte interferon with FS-4 fibroblasts. J Gen Virol 44: 161–168PubMedGoogle Scholar
  187. Garren LD, Howell RR, Tomkins GM, Crocco RM (1964) A paradoxical effect of actinomycin D: the mechanism of regulation of enzyme synthesis by hydrocortisone. Proc Natl Acad Sci USA 52: 1121–1129PubMedGoogle Scholar
  188. Gatmaitan BG, Stanley ED, Jackson GG (1973) The limited effect of nasal interferon induced by rhinovirus and a topical chemical inducer on the course of infection. J Infect Dis 127: 401–407PubMedGoogle Scholar
  189. Gazdar AF, Steinberg AD, Spahn GF, Baron S (1972) Interferon inducers: enhancement of viral oncogenesis in mice and rats. Proc Soc Exp Biol Med 139 (4): 1132–1137PubMedGoogle Scholar
  190. Gazdar AF, Sims M, Spahn GJ, Baron S (1973) Interferon mediates enhancement of tumor growth and virus-induced sarcomas in mice. Nature New Biol 245 (142): 77–78PubMedGoogle Scholar
  191. Gidlund M, Om A, Wigzell H, Senik A, Gresser I (1978) Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 273: 759–764PubMedGoogle Scholar
  192. Gisler RH, Lindahl P, Gresser I (1974) Effects of interferon on antibody synthesis in vitro. J Immunol 113: 438–444PubMedGoogle Scholar
  193. Glasgow LA (1971) Immunosuppression, interferon, and viral infections. Fed Prod 30: 1846–1851Google Scholar
  194. Glasgow LA, Habel K (1962) Interferon production by mouse leukocytes in vitro and in vivo. J Exp Med 117: 149–160Google Scholar
  195. Glasgow LA, Crane JL Jr, Schleupner CJ, Kern ER, Youngner JS, Feingold DS (1979) Enhancement of resistance to murine osteogenic sarcoma in vivo by an extract of Brucella abortus (Bru-Pel): association with activation of reticuloendothelial system macrophages. Infection and Immunity 23: 19–26PubMedGoogle Scholar
  196. Gordon I, Stevenson D (1980) Kinetics of decay in the expression of interferon-dependent mRNAs responsible for resistance to virus. Proc Natl Acad Sci USA 77: 452–456PubMedGoogle Scholar
  197. Graessmann A, Graessmann M, Hoffmann H, Niebel J, Brandner G, Mueller N (1974) Inhibition by interferon of SV40 tumor antigen formation in cells injected with SV40 cRNA transcribed in vivo. FEBS Letters 39: 249–251PubMedGoogle Scholar
  198. Gravell M, Cromeans TL (1972) Inhibition of early viral ribonucleic acid synthesis in interferon treated cells infected with frog polyhedral cytoplasmic deoxyribovirus. Virology 50: 916–919PubMedGoogle Scholar
  199. Graves HE, Meager A (1980) Interferon production by human-mouse hybrid cells: dominant mouse control of superinduction and priming. J Gen Virol 47: 489–495PubMedGoogle Scholar
  200. Green JA, Cooperband SR, Kibrick S (1969) Immune-specific induction of interferon production in cultures of human blood lymphocytes. Science 164: 1415–1417PubMedGoogle Scholar
  201. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC (1976) Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. New Engl J Med 295: 517–522PubMedGoogle Scholar
  202. Greene JJ, Dieffenbach CW, Ts’o POP (1978) Inactivation of interferon mRNA in the shutoff of human interferon synthesis. Nature 271: 81–83PubMedGoogle Scholar
  203. Gresser I (1961) Production of interferon by suspensions of human leukocytes. Proc Soc Exp Biol Med 108: 799–803PubMedGoogle Scholar
  204. Gresser I (1977) On the varied biologic effect of interferon. Cellular Immunol 34:406–415Google Scholar
  205. Gresser I, Bourali C (1969) Exogenous interferon and inducers of interferon in the treatment of Balb/c mice inoculated with RC19 tumor cells. Nature 223: 844–846PubMedGoogle Scholar
  206. Gresser I, Bourali C (1970) Antitumor effects of interferon preparation in mice. J Natl Cancer Inst 45: 365–375PubMedGoogle Scholar
  207. Gresser I, Bourali-Maury C (1972) Inhibition by interferon preparations of a solid malignant tumor and pulmonary metastasis in mice. Nature New Biol 236: 78–79PubMedGoogle Scholar
  208. Gresser I, Tovey MG (1978) Antitumor effects of interferon. Biochim Biophys Acta 516: 231–247PubMedGoogle Scholar
  209. Gresser I, Coppey Y, Falcoff E, Fontaine D ( 1967 a) Interferon and murine leukemia. I. Inhibitory effect of interferon preparations on development of Friend leukemia in mice. Proc Soc Exp Biol Med 124: 84–91PubMedGoogle Scholar
  210. Gresser I, Fontaine D, Coppey Y, Falcoff R, Falcoff E ( 1967 b) Interferon and murine leukemia. II. Factors related to the inhibitory effect of interferon preparations on development of Friend leukemia in mice. Proc Soc Exp Biol Med 124: 91–94PubMedGoogle Scholar
  211. Gresser I, Coppey J, Brouty-Boyé DF, Falcoff R ( 1967 c) Interferon and murine leukemia. III. Efficacy of interferon preparations administered after inoculation of Friend virus. Nature 215: 174–175PubMedGoogle Scholar
  212. Gresser I, Falcoff R, Brouty-Boyé DF, Zaydela F, Coppey Y, Falcoff E ( 1967 d) Interferon and murine leukemia. IV. Further studies on the efficacy of interferon preparations administered after inoculation of Friend virus. Proc Soc Exp Biol Med 126: 791–797Google Scholar
  213. Gresser I, Berman L, DeThe G, Brouty-Boyé D, Coppey Y, Falcoff E ( 1968 a): Interferon and murine leukemia. V. Effect of interferon preparations on the evolution of Rauscher disease in mice. J Nat Cancer Inst 41: 505–509PubMedGoogle Scholar
  214. Gresser I, Bourali C, Thomas MT, Falcoff E (1968 b) Effect of repeated inoculation of interferon preparations on infection of mice with encephalomyocarditis virus. Proc Soc Exp Biol Med 127:491–496Google Scholar
  215. Gresser I, Bourali C, Levy JP (1969 a) Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc Natl Acad Sci USA 63:51–56Google Scholar
  216. Gresser I, Coppey J, Bourali C ( 1969 b) Interferon and murine leukemia. VI. Effect of interferon preparations on the lymphoid leukemia of AKR mice. J Natl Cancer Institut 43: 1083–1089PubMedGoogle Scholar
  217. Gresser I, Brouty-Boyé D, Thomas MT, Macieira-Coehlo A (1970) Interferon and cell division. I. Inhibiton of the multiplication of mouse leukemia L1210 cells in vitro by interferon. Proc Nat Acad Sci USA 66: 1052–1058PubMedGoogle Scholar
  218. Gresser I, Thomas MT, Brouty-Boyé D (1971) Effect of interferon on L1210 cells in vitro on tumor and colony formation. Nature 231: 20–21Google Scholar
  219. Gresser I, Bandu MT, Brouty-Boy D, Tovey M (1974 a) Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature 251:543–545PubMedGoogle Scholar
  220. Gresser I, Bandu MT, Brouty-Boyé D (1974b) Interferon and cell division. IX. Interferonresistant L1210 cells: characteristics and origin. J Natl Cancer Inst 52: 553–559PubMedGoogle Scholar
  221. Gresser I, Tovey MG, Maury C, Chouroulinkov I (1975a) Lethality of interferon prepara-tions for newborn mice. Nature 258: 76–78PubMedGoogle Scholar
  222. Gresser I, Tovey MG, Bourali-Maury C ( 1975 b) Efficacy of exogenous infection. Treatment initiated after onset of multiplication of vesicular stomatitis virus in the brains of mice. J Gen Virol 27: 395–398PubMedGoogle Scholar
  223. Gresser I, Maury C, Tovey M, Morel-Maroger L, Pontillon F (1976a) Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 263: 420–422PubMedGoogle Scholar
  224. Gresser I, Tovey MG, Bandu MT, Maury C, Brouty-Boyé D (1976b) Role of interferon in the pathogenesis of virus disease in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of EMC virus infection. J Exp Med 144: 1305–1315PubMedGoogle Scholar
  225. Gresser I, Maury C, Tovey M (1976c) Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in AKR mice. Int J Cancer 17: 647–653PubMedGoogle Scholar
  226. Gresser I, Maury C, Tovey MG (1978 a) Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Europ J Cancer 14:97–102Google Scholar
  227. Gresser I, Maury C, Bandu MT, Tovey M, Maunoury MT (1978b) Role of endogenous interferon in the antitumor effect of Poly I-C and statolon as demonstrated by the use of anti-mouse interferon serum. J Natl Cancer Inst 21: 72–77Google Scholar
  228. Grollmann EF, Lee G, Ramos S, Lazo PS, Kaback HR, Friedman R, Kohn LD (1978) Relationships of the structure and function of the interferon receptor to hormone receptors and the establishment of the antiviral state. Cancer Res 38: 4172–4185Google Scholar
  229. Grossberg SE, Holland JJ (1962) Interferon and viral ribonucleic acid. Effect on virus-susceptible and insusceptible cells. J Immunol 88: 708–714PubMedGoogle Scholar
  230. Gupta SL, Sopori ML, Lengyel P (1973) Inhibition of protein synthesis directed by added viral and cellular messenger RNAs in extracts of interferon-treated Ehrlich ascites tumor cells. Biochem Biphys Res Commun 54: 777–783Google Scholar
  231. Gupta SL, Graziadei WD III, Weideli H, Sopori ML, Lengyel P (1974) Selective inhibition of viral protein accumulation in interferon treated cells; nondiscriminate inhibition of the translation of added viral and cellular messenger RNAs in their extracts. Virology 57: 49–63PubMedGoogle Scholar
  232. Gupta SL, Rubin BY, Holmes SL (1979) Interferon action: induction of specific proteins in mouse and human cells by homologous interferons. Proc Natl Acad Sci USA 76: 4817–4821PubMedGoogle Scholar
  233. Gutterman JU, Blumenchein GR, Alexanian R, Yap H-Y, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S (1980) Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Int Med, 93: 399–406PubMedGoogle Scholar
  234. Haller O, Arnheiter H, Gresser I, Lindenmann J (1979) Genetically determined, interferon-dependent resistancce to influenza virus in mice. J Exp Med 149: 601–612PubMedGoogle Scholar
  235. Haller O, Arnheiter H, Lindenmann J, Gresser I (1980) Host gene influences sensitivity to interferon action selectively for influenza virus. Nature 283: 660–662PubMedGoogle Scholar
  236. Hamdy AH, Stringfellow DA (1980) Effect of 2-amino-5-bromo-6-phenyl-4-pyrimidinol in calves infected with infectious bovine rhinotracheitis virus. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious diseases, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, vol II. The American Society for Microbiology, Washington DC, pp 1404–1406Google Scholar
  237. Hamilton RD, Buthala DA, Eidson EE, Tomilo A, Andrews JC (1980) Interferon induction in vitro with 6-methyl-and 6-arylpyrimidines. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious diseases, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, vol II. The American Society for Microbiology, Washington DC, pp 1409–1411Google Scholar
  238. Harmon MW, Greenberg SB, Johnson PE, Couch RB (1977) Human nasal epithelial cell culture system: evaluation of response to human interferons. Infec Immun 16: 480–485Google Scholar
  239. Harrington DL, Crabbs CL, Hilmas DE, Brown JR, Higbee CA, Cole EF Jr, Levy HB (1979) Adjuvant effects of low doses of a nuclease resistant derivative of polyinosinic polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan Equine Encephalomyelitis virus vaccine. Infect Immun 24: 60–66Google Scholar
  240. Havell EA (1977) Cellular regulation mechanisms controlling synthesis of interferons. In: Stewart WE II (ed) Interferons and their actions. CRC Press, Inc, Cleveland, Ohio, pp 37–48Google Scholar
  241. Havell EA, Vilcek J (1972) Production of high-titered interferon in cultures of human diploid cells. Antimicrob Agents Chemother 2: 476–484PubMedGoogle Scholar
  242. Havell EA, Vilcek J (1975) Inhibition of interferon secretion by vinblastine. J Cell Biol 64: 716–721PubMedGoogle Scholar
  243. Havell EA, Berman B, Ogburn CA, Berg K, Paucker K, Vilcek J (1975) Two antigenically distinct species of human interferon. Proc Natl Acad Sci USA 72: 2185–2190PubMedGoogle Scholar
  244. EA, Yamazaki S, Vilcek J (1977) Altered molecular species of human interferon produced in the presence of inhibitors of glycosylation. J Biol Chem 252: 4425–4433PubMedGoogle Scholar
  245. Havell EA, Yip YK, Vilcek J ( 1978 a) Characteristics of human lymphoblastoid ( Namalva) interferon. J Gen Vriol 38: 51–60Google Scholar
  246. Havell EA, Hayes TG, Vilcek J (1978b) Synthesis of two distinct interferons by human fibroblasts. Virology 89: 330–334PubMedGoogle Scholar
  247. Hayes TG, Yip YK, Vilcek J (1979) Le interferon production by human fibroblasts. Virology 98:351–363PubMedGoogle Scholar
  248. Henderson DR, Joklik WK (1978) The mechanism of interferon induction by UV-irradiated reovirus. Virology 91: 389–406PubMedGoogle Scholar
  249. Henle G, Henle W (1965) Evidence for a persistent viral infection in a cell line derived from Burkitt’s lymphoma. J Bacteriol 89: 252–260Google Scholar
  250. Heron I, Berg K, Cantell K (1976) Regulation effect of interferon on T cell in vitro. J Immunol 117: 1370–1377PubMedGoogle Scholar
  251. Heron I, Hokland M, Berg K (1978) Enhanced expression of ß2-microglobulin and HLA antigen on human lymphoid cells by interferon. Proc Natl Acad Sci USA 75: 6215–6219PubMedGoogle Scholar
  252. Hilfenhaus J, Karges HE, Weinmann E, Barth R (1975) Effect of administered human leukocyte interferon on experimental rabies in monkeys. Infect Immun 11: 1156–1162PubMedGoogle Scholar
  253. Hilfenhaus J, Damm H, Johannsen R (1977) Sensitivities of various human lymphoblastoid cells to the antiviral and anticellular activity of human leukocyte interferon. Arch Virol 54: 271–277PubMedGoogle Scholar
  254. Hill NO, Loeb E, Pardue A, Khan A, Dorn GL, Comparini S, Hill JM (1978) Leukocyte interferon production and its effectiveness in acute lymphatic leukemia. J Clin Hemat Onc 8: 66Google Scholar
  255. Hitchcock G, Isaacs A (1960) Protection of mice against the lethal action of an encephalitis virus. Brit Med J II:1268–1270Google Scholar
  256. Ho M (1961) Inhibition of the infectivity of poliovirus RNA by interferon. Proc Soc Exp Biol Med 107: 639–644PubMedGoogle Scholar
  257. Ho M, Armstrong JA (1975) Interferon. Ann Rev Microbiol 29: 131–161Google Scholar
  258. Ho M, Enders JF (1959 a) An inhibitor of viral activity appearing in infected cell cultures. Proc Natl Acad Sci USA 45:385–389PubMedGoogle Scholar
  259. Ho M, Enders JF (1959 b) Further studies on an inhibitor of viral activity appearing in infected cell cultures and its role in chronic viral infection. Virology 9:446–477PubMedGoogle Scholar
  260. Ho M, Kono Y (1965) Effect of actinomycin D on virus and endotoxin-induced interferon like inhibitors in rabbits. Proc Natl Acad Sci USA 53: 220–224PubMedGoogle Scholar
  261. Ho M, Kono Y, Breinig MK (1965) Tolerance to the induction of interferons by endotoxin and virus: role of a humoral factor. Proc Soc Exp Biol Med 119: 1227–1232PubMedGoogle Scholar
  262. Ho M, Breinig MK, Postic B, Armstrong JA (1970) The effect of preinjections on the stimulation of interferon by a complexed polynucleotide, endotoxin, and virus. Ann NY Acad Sci 173: 680–688Google Scholar
  263. Horoszewicz JS, Leong SS, Carter WA (1979) Noncycling tumor cells are sensitive targets for the antiproliferative activity of human interferon. Science 206: 1091–1093PubMedGoogle Scholar
  264. Horvath SE, Friedman RM (1971) Nucleic acid and proteins isolated from a strain of murine sarcoma virus ( MSV-O ). Proc Soc Exp Biol Med 137: 1075–1081PubMedGoogle Scholar
  265. Hoskins M (1935) A protective action of neurotropic against viscerotropic yellow fever virus in Macacus rhesus. Amer J Trop Med Hyg 15: 675–680Google Scholar
  266. Houghton M, Stewart AG, Doel SM, Emtage JS, Eaton MAW, Smith JC, Patel TP, Lewis HM, Poster AG, Birch JR, Cartwright T, Carey NH (1980) The amino-terminal sequence of human fibroblast interferon as deduced from reverse transcripts obtained using synthetic oligonucleotide primers. Nuc Acids Res 8: 1913–1931Google Scholar
  267. Houston WE, Crabbs CL, Stephen SL, Levy HB (1976) Modified polyriboinosinicpolyribocytidylic acid, an immunologic adjuvant. Infec Immun 14: 318–319Google Scholar
  268. Hovanessian AR, Kerr IM (1979) The (2’5’)Oligoadenylate (pppA2’-5’A2’5’A) synthetase and protein kinase(s) from interferon-treated cells. Eur J Biochem 93: 515–526PubMedGoogle Scholar
  269. Hovanessian AG, Brown RE, Kerr IM (1977) Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature 268: 537–540PubMedGoogle Scholar
  270. Hovanessian AG, Wood J, Meurs E, Montagnier L (1979) Increased nuclear activity in cells treated with pppA2’p5’A2’p5’A. Proc Natl Acad Sci USA 76: 3261–3265PubMedGoogle Scholar
  271. Huang JW, Davey MW, Hejna CJ, Von Muenchhausen W, Sulkowski E, Carter WA (1974) Selective binding of human interferon to albumin immobilized on agarose. J Biol Chem 249: 4665–4667PubMedGoogle Scholar
  272. Huang KY, Donahoe RM, Gordon FB, Dressler HR (1971) Enhancement of phagocytosis by interferon-containing preparations. Infect Immunity 4: 581–588Google Scholar
  273. Huet C, Gresser I, Bandu MT, Lindahl P (1974) Increased binding of concanavalin A to interferon-treated murine leukemia L1210 cells. Proc Soc Exp Biol Med 147: 52–57PubMedGoogle Scholar
  274. Hunt T, Ehrenfeld F (1971) Cytoplasm from poliovirus infected HeLa cells inhibits cell-free haemoglobin synthesis. Nature 230: 91–94Google Scholar
  275. Hutchinson DW, Merigan TC (1975) The lack of antiviral effect of poly I poly C when attached to insoluble supports. J Gen Virol 27: 403–410PubMedGoogle Scholar
  276. Ida S, Hooks JJ, Siraganian RP, Notkins AL (1977) Enhancement of IgE mediated histamine release from human basophils by viruses: role of interferon. J Exp Med 145: 892–906PubMedGoogle Scholar
  277. Ikic D, Smerdel S, Rajninger-Miholic M, Soos E, Jusic D (1975a): Treatment of labial and genital herpes with human leukocytic interferon. In: Proceedings of the symposium on clinical use of interferon. Yugoslav Academy of Sciences and Arts, Zagreb, pp 195–202Google Scholar
  278. Ikic D, Bosnic N, Smerdel S, Jusic D, Soos E, Delimar N (1975b) Double blind clinical study with human leukocyte interferon in the therapy of condylomata acuminata. In: Proceedings of the symposium on clinical use of interferon. Yugoslav Academy of Sciences and Arts, Zagreb, pp 229–233Google Scholar
  279. Illinger D, Coupin G, Richards M, Poindron P (1976) Rat interferon inhibits steroid-inducible glycerol 3-phosphate dehydrogenase synthesis in a rat glial cell line. FEBS Letters 64: 391–395PubMedGoogle Scholar
  280. Imanishi J, Yokota Y, Kishida T, Mukainaka T, Matsuo A (1975): Phagocytosis-enhancing effect of human leukocyte interferon preparation on human peripheral monocytes in vitro. Acta Virology 19: 52–55Google Scholar
  281. Ingimarsson S, Cantell K, Strander H (1979) Side effects of long-term treatment with human leukocyte interferon. J Infect Dis 140: 560–563PubMedGoogle Scholar
  282. Isaacs A, Burke DC (1958) Mode of action of interferon. Nature 182: 1073–1074PubMedGoogle Scholar
  283. Isaacs A, Lindenmann J (1957) Virus interference I. The interferon. Proc Roy Soc Serie B 147: 258–267Google Scholar
  284. Isaacs A, Westwood MA (1959) Inhibition by interferon of the growth of vaccinia virus in the rabbit skin. Lancet II:324–325Google Scholar
  285. Isaacs A, Lindenmann J, Valentine RC (1957) Virus interference II. Some properties of interferon. Proc Roy Soc Series B 147: 268–273Google Scholar
  286. Ito Y, Nishiyama Y, Shimokata K, Kimura Y, Nagata I, Kunii A (1976) The effects of cytochalasin and colchicine on interferon production. J Gen Virol 33: 1–9PubMedGoogle Scholar
  287. Iwakura Y, Yonehara S, Kawade Y (1978) Presence of a common structure in the two molecular species of mouse L cell interferon. Biochem Biophys Res Commun 84: 557–563PubMedGoogle Scholar
  288. Jameson P, Grossberg SE (1979) Production of interferon by human tumor cell lines. Arch Virol 62: 209–219PubMedGoogle Scholar
  289. Jameson P, Schoenherr CK, Grossberg SE (1977) Bluetongue virus induction of interferon and resistance to viral infection. Interferon Workshop, Lake Placid, NYGoogle Scholar
  290. Jameson P, Schoenherr CK, Grossberg SE (1978) Bluetongue virus, an exceptionally potent interferon inducer in mice. Infection and Immunity 20: 321–323PubMedGoogle Scholar
  291. Jameson P, Taylor JL, Dixon M, Sedmak J, Grossberg SE (1980) Bluetongue virus, a potent inducer of leukocyte and fibroblastoic interferons. In: Khan A, Hill NO, Dorn GL (eds) Interferon: properties and clinical uses. Proceedings of the International Symposium on Interferons, Wadley Institutes of Molecular Medicine. Leland Fikes Foundation Press, Dallas, pp 11–20Google Scholar
  292. Jameson P, Taylor JL, Grossberg SE (1981) Bluetongue virus induction of interferon: Potential for cancer therapy. In: Hersh EM, Chirigos M, Mastrangelo M (eds) Augmenting agents in cancer therapy. Current status and future prospects, Vol 16. Raven Press, New York, pp 193–203Google Scholar
  293. Jankowski WJ, Davey MW, O’Malley J, Sulkowski E, Carter WA (1975) Molecular structure of human fibroblast and leukocyte interferons: probe by lectin and hydrophobic chromatography. J Virol 16: 1124–1130PubMedGoogle Scholar
  294. Jarvis AP, Colby C (1978) Regulation of the murine interferon system: isolation and characterization of a mutant 3T6 cell engaged in the semiconstitutive synthesis of interferon. Cell 14: 355–364PubMedGoogle Scholar
  295. Jarvis AP, White C, Ball A, Gupta SL, Ratner L, Sen GC, Colby C (1978) Interferon associated, dsRNA-dependent enzyme activities in a mutant 3T6 cell engaged in the semiconstitutive synthesis of interferon. Cell 14: 879–887PubMedGoogle Scholar
  296. Johnson HM (1977) Effect of interferon on antibody formation. Tex Rep Biol Med 35: 357–365PubMedGoogle Scholar
  297. Johnson HM, Smith BG, Baron S (1975) Inhibition of primary in vitro antibody response by interferon preparations. J Immunol 114: 403–409PubMedGoogle Scholar
  298. Johnston MD, Atherton KT, Hutchinson DW, Burke DC (1976) The binding of poly I poly C to human fibroblasts and the induction of interferon. Biochim Biophys Acta 435: 69–73PubMedGoogle Scholar
  299. Johnston MI, Stollar BD (1978) Antigenic structure of double-stranded RNA analogues having varying activity in interferon inducers. Biochem 17: 1959–1964Google Scholar
  300. Joklik WK, Merigan TC (1966) Concerning the mechanism of action of interferon. Proc Natl Acad Sci USA 56: 558–565PubMedGoogle Scholar
  301. Jones BR, Coster DJ, Falcon MG, Cantell K (1976) Topical therapy of ulcerative herpetic keratitis with human interferon. Lancet 2: 128PubMedGoogle Scholar
  302. Jordan GW, Fried RP, Merigan TC (1974) Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating antiviral activity, and host responses to infection. J Infect Dis 130: 56–62PubMedGoogle Scholar
  303. Kajander A, Von Essen R, Isomäki H, Cantell K (1979) Interferon treatment of rheumatoid arthritis. Lancet 1: 984–985PubMedGoogle Scholar
  304. Kaufman HE, Meyer RF, Laibson PR, Waltman SR, Nesburn AB, Shuster JJ (1976) Human leukocyte interferon for the prevention of recurrences of herpetic keratitis. J Infect Dis 133: A165 - A168PubMedGoogle Scholar
  305. Kawakita M, Cabrer B, Taira H, Rebello M, Slattery E, Weideli H, Lengyel P (1978) Purification of interferon from mouse Ehrlich ascites tumor cells. J Biol Chem 253: 598–602PubMedGoogle Scholar
  306. Keleti G, Feingold DS, Youngner JS (1974) Interferon induction in mice by lipopolysaccharide from Brucella abortus. Infection and Immunity 10: 282–283PubMedGoogle Scholar
  307. Keleti G, Feingold DS, Youngner JS (1977) Antitumor activity of a Brucella abortus preparation. Infection and Immunity 15: 846–849PubMedGoogle Scholar
  308. Kern ER, Richards JT, Overall JC Jr, Glasgow LA (1978) Alteration of mortality and pathogenesis of three experimental Herpesvirus hominis infections of mice with adenine or arabinoside 5’monophosphate, adenine arabinoside, and phosphonoacetic acid. Antimicrob Agents Chemother 13: 53–60PubMedGoogle Scholar
  309. Kerr IM, Brown RE (1978) pppA2’p5’p2’p5’A: An inhibitor of protein synthesis synthesized with an enzyme fraction from interferon treated cells. Proc Natl Acad Sci USA 75: 256–260PubMedGoogle Scholar
  310. Kerr IM, Brown RE, Ball LA (1974) Increased sensitivity of cell free protein synthesis to double stranded RNA after interferon treatment. Nature 250: 57–59PubMedGoogle Scholar
  311. Kerr IM, Brown RE, Hovanessian AG (1977) Nature of inhibitor of cell free protein synthesis found in response to interferon and double stranded RNA. Nature 268: 540–542PubMedGoogle Scholar
  312. Killander D, Lindahl P, Lundin L, Leary P, Gresser I (1976) Relationship between the enhanced expression of histocompatibility antigens of interferon-treated L1210 cells and their position in the cell cycle. Eur J Immunol 6: 56–59PubMedGoogle Scholar
  313. Kimchi A, Shulman L, Schmidt A, Chernajovsky Y, Fradin A, Revel M (1979) Kinetics of the induction of three translation-regulatory enzymes by interferon. Proc Natl Acad Sci USA 76: 3208–3212PubMedGoogle Scholar
  314. Kingham JGC, Ganguly NK, Shaari ZD, Holgate ST, McGuire MJ, Mendelson R, Cartwright T, Scott GM, Richards BM, Wright R (1978) Treatment of HBsAG-positive chronic active hepatitis with human fibroblast interferon. Gut 19: 91–94PubMedGoogle Scholar
  315. Kingsman SM, Samuel CE (1980) Mechanism of interferon action. Interferon-mediated inhibition of simian virus 40 early RNA accumulation. Virology 101: 458–465PubMedGoogle Scholar
  316. Kishida T, Kato S, Nagano Y (1965) Effet du facteur inhibiteur du virus sur le fibrome de Shope. C.R. Soc Biol 159: 782–784Google Scholar
  317. Kishida T, Toda S, Toida T, Hattori T (1971) Effect of interferon on malignant mouse cells. C.R. Soc Biol (Paris) 165: 1489–1492Google Scholar
  318. Klein G, Viléek J (1980) Attempts to induce interferon production by IdUrd induction and EBV superinfection in human lymphoma lines and their hybrids. J Gen Virol 46: 111–117PubMedGoogle Scholar
  319. Knight E Jr (1973) Interferon: effect on the saturation density to which mouse cells will grow on vitro. J Cell Biol 56: 846–849PubMedGoogle Scholar
  320. Knight E Jr (1974) Interferon sepharose: induction of the antiviral state. Biochem Biophys Res Commun 56: 860–864PubMedGoogle Scholar
  321. Knight E Jr (1976 a) Interferon purification and initial characterization from human diploid cells. Proc Natl Acad Sci USA 73:520–523Google Scholar
  322. Knight E Jr (1976 b) Antiviral and cell growth inhibitory activities reside in the same glycoprotein of human fibroblast interferon. Nature 262:302–303Google Scholar
  323. Knight E Jr (1978) Preparation of 125lodine-labeled human fibroblast interferon. J Gen Virol 40: 681–684PubMedGoogle Scholar
  324. Knight E Jr, Korant BD (1977) A cell surface alteration in mouse L cells induced by interferon. Biochim Biophys Res Commun 74: 707–713Google Scholar
  325. Knight E Jr, Korant BD (1979) Fibroblast interferon induces synthesis of four proteins in human fibroblast cells. Proc Natl Acad Sci 76: 1824–1827PubMedGoogle Scholar
  326. Knight E Jr, Hunkapiller MW, Korant BD, Hardy RWF, Hood LE (1980) Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence. Science 207: 525–526PubMedGoogle Scholar
  327. Knight E Jr, Korant BD (1979) Fibroblast interferon induces synthesis of four proteins in human fibroblast cells. Proc Natl Acad Sci 76: 1824–1827PubMedGoogle Scholar
  328. Kobza K, Emödi G, Just M, Hilti E, Leuenberger A, Binswanger U, Thiel G, Brunner FP (1975) Treatment of herpes infection with human exogenous interferon. Lancet 1:1343–1344PubMedGoogle Scholar
  329. Kohase M, Vilcek J (1979) Interferon induction with Newcastle disease virus in FS-4 cells: effect of 5,6-dichloro-l-ß-D-ribofuranosylbenzimidazole ( DRB ). Arch Virol 62: 263–271PubMedGoogle Scholar
  330. Kohn LD, Friedman RM, Holmes JM, Lee G (1976) Use of thyrotropin and cholera toxin to probe the mechanism by which interferon initiates its antiviral activity. Proc Natl Acad Sci USA 73: 3695–3699PubMedGoogle Scholar
  331. Kohno S, Shirasawa N, Umino Y, Matsuno T, Kohase M (1975) Binding of polyribosinosinic-polyribocytidylic acid with cultured cells. Arch Virol 49: 229–237PubMedGoogle Scholar
  332. Kramer MJ, Cleeland R, Grunberg S (1976) Antiviral activity of 10-carboxymethyl-9-acridanone. Antimicrob Agents Chemother 9: 233–238PubMedGoogle Scholar
  333. Krim M, Sanders FK (1977) Prophylaxis and therapy with interferons. In: Stewart WE II (ed) Interferons and their actions. CRC Press, Cleveland, Ohio, pp 153–201Google Scholar
  334. Kroath H, Gross HJ, Jungwirth C, Bodo G (1978) RNA methylation in vaccinia virus-infected chick embryo fibroblasts treated with homologous interferon. Nuc Acids Res 5: 2441–2454Google Scholar
  335. Kronenberg L, Friedmann T (1975) Relative quantitative assay of the biological activity of interferon messenger RNA. J Gen Virol 27: 225–232PubMedGoogle Scholar
  336. Krown SE, Stoopler MB, Cunningham-Rundles S, Oettgen HF (1980) Phase II trial of human leukocyte interferon (IF) in non-small cell lung cancer ( NSCLC ). Proc Amer Assoc Can Res 21: 179Google Scholar
  337. Krueger RF, Mayer GD (1970) Tilorone hydrochloride: an orally active antiviral agent. Science 169: 1213–1214PubMedGoogle Scholar
  338. Lai MH, Joklik WK (1973) The induction of interferon by temperature-sensitive mutants of reovirus, UV-irradiated and subviral reovirus particles. Virology 51: 191–212PubMedGoogle Scholar
  339. Lampson GP, Tytell AA, Nemes MM, Hillemann MR (1963) Purification and characteriza-tion of chick embryo interferon. Proc Soc Exp Biol Med 112: 468–481PubMedGoogle Scholar
  340. Larson VM, Clark WR, Dagle GE, Hilleman MR (1969) Influence of synthetic double-stranded ribonucleic acid, poly I:C on Friend leukemia in mice. Proc Soc Exp Biol Med 132: 602–607PubMedGoogle Scholar
  341. Larsson A, Forsgren M, Hard of Segerstad S, Strander H, Cantell H (1976) Administration of interferon to an infant with congenital rubella syndrome involving persistent viremina and cutaneous vasculitis. Acta Paediatr Scand 65: 105–110Google Scholar
  342. Lebleu B, Sen GC, Shaila S, Cabrer B, Lengyel P (1976) Interferon, double stranded RNA and protein phosphorylation. Proc Natl Acad Sci USA 73: 3107–3111PubMedGoogle Scholar
  343. Lebleu B, Hubert E, Content J, De Wit L, Braude IA, De Clercq E (1978) Translation of mouse interferon mRNA in Xenopus laevis oocytes and in rabbit reticulocyte lysates. Biochem Biophys Res Comm 82: 665–673PubMedGoogle Scholar
  344. Lebon P, Moreau MC, Cohen L, Chany C (1975) Different effect of ouabain on interferon production and action. Proc Soc Exp Biol Med 149: 108–112PubMedGoogle Scholar
  345. Lefkowitz E, Worthington M, Confiffe MA, Baron S (1976) Comparative effectiveness of six antiviral agents in herpes simplex TYPE 1 infection of mice. Proc Soc Exp Biol Med 152: 337–352PubMedGoogle Scholar
  346. Lerner AM, Bailey EJ (1974) Synergy of a 9-Beta-D-Arabinofuranosyladenine and human interferon against herpes simplex virus type 1. J Infect Dis 130: 549–552PubMedGoogle Scholar
  347. Levine DW, Wong JS, Wang DIC, Thilly WG (1977) Microcarrier cell culture: new methods for research scale application. Somatic Cell Genet 3: 149–155PubMedGoogle Scholar
  348. Levy HB, Lvovsky E (1978) Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. J Infect Dis 137: 78–81PubMedGoogle Scholar
  349. Levy HB, Buckler CE, Baron S (1966) Effect of interferon on early interferon production. Science 152: 1274–1276PubMedGoogle Scholar
  350. Levy HB, Baer G, Baron S, Buckler CE, Gibbs CJ, Iadorola MJ, London WT, Rice J (1975) A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 132: 434–439PubMedGoogle Scholar
  351. Levy HB, London W, Fuccillo DA, Baron S, Rice J (1976) Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer, polyriboinosinic • polyribocytidylic acid-poly-L-lysine. J Infect Dis [Suppl] 133: A256 - A259Google Scholar
  352. Levy HB, Lvovsky E, Riley F, Harrington D, Anderson A, Moe J, Hilfenhaus J, Stephen E (1980) Immune modulating effects of poly ICLC. Ann NY Acad Sci 350: 33–41PubMedGoogle Scholar
  353. Lieberman M, Merigan TC, Kaplan HS (1971) Inhibition of radiogenic lymphoma development in mice by interferon. Proc Soc Exp Biol Med 138: 575–578PubMedGoogle Scholar
  354. Lieberman D, Voloch Z, Aviv H, Nudel U, Revel M (1974) Effect of interferon on hemoglobin synthesis and leukemia virus production in Friend cells. Mol Biol Rep 1: 447–451PubMedGoogle Scholar
  355. Lin LS, Stewart WE II (1978) Two dimensional gel electrophoresis of human leukocyte interferon. Abstr Ann Meeting Amer Soc Biol ChemGoogle Scholar
  356. Lin LS, Wiranowska-Stewart M, Chudzio T, Stewart WE II (1978) Characterization of the heterogenous molecules of human interferons: differences in the cross-species antiviral activities of various molecular populations in human leukocyte interferons. J Gen Virol 39: 125–130PubMedGoogle Scholar
  357. Lindahl P, Leary P, Gresser I (1972) Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 69: 721–725PubMedGoogle Scholar
  358. Lindahl P, Leary P, Gresser I (1973) Enhancement by interferon of the expression of surface antigens on murine leukemia L1210 cells. Proc Natl Acad Sci USA 70: 2785–2788PubMedGoogle Scholar
  359. Lindahl P, Leary P, Gresser I (1974) Enhancement of the expression of histocompatibility antigen of mouse lymphoid cells by interferon in vitro. Eur J Immunol 4: 779–794Google Scholar
  360. Lindahl P, Gresser I, Leary P, Tovey M (1976 a) Enhanced expression of histocompatibility antigens of lymphoid cells in mice treated with interferon. J Infect Dis 133:A66–A72PubMedGoogle Scholar
  361. Lindahl P, Gresser I, Leary P, Tovey M (1976 b) Interferon treatment of mice-enhanced expression of histocompatibility antigens on lymphoid cells. Proc Natl Acad Sci 73:1284–1299PubMedGoogle Scholar
  362. Lindahl-Magnusson P, Leary P, Gresser I (1972) Interferon inhibits DNA synthesis in mouse lymphocyte suspensions by phytohaemagglutinin or by allogeneic cells. Nature New Biol 273: 120–121Google Scholar
  363. Lindenmann J, Burke D, Isaacs A (1957) Studies on the production, mode of action and properties of interferon. Brit J Exp Path 38: 551–562PubMedGoogle Scholar
  364. Lindner-Frimmel SJ (1974) Enhanced production of human interferon by UV-irradiated cells. J Gen Virol 25: 147–150PubMedGoogle Scholar
  365. Liu J-L (1978) Effects of mouse serum interferon and interferon inducers on dengue and Japanese encephalitis virus infections in weanling mice. Kobe J Med Sci 24: 153–163PubMedGoogle Scholar
  366. Lockart RZ Jr (1964) The necessity for cellular RNA and protein synthesis for viral inhibition from interferon. Biochem Biophys Res Commun 15: 513–518Google Scholar
  367. Lockart RZ Jr (1966) Biological properties of interferons: criteria for acceptance of a viral inhibitor as an interferon. In: Finter NB (ed) Interferons, North-Holland Publ Co, Amsterdam, pp 1–20Google Scholar
  368. Lockart RZ Jr, Bayliss NL, Toy ST, Yin FH (1968) Viral events necessary for the induction of interferon in chick embryo cells. J Virol 2: 962–965PubMedGoogle Scholar
  369. Lomniczi B, Burke DC (1970) Interferon production by temperature-sensitive mutants of Semliki Forest virus. J Gen Virol 8: 55–68PubMedGoogle Scholar
  370. Lotem J, Sachs L (1978) Genetic dissociation of different cellular effects of interferon on myeloid leukemic cells. Int J Cancer 22: 214–220PubMedGoogle Scholar
  371. Loughman BE, Gibbons AJ, Taggart MT, Renis HE (1980) Modulation of mouse natural killer cell activity by interferon and two antiviral isocytosines. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious diseases, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, vol II. The American Society for Microbiology, Washington DC, pp 1398–1400Google Scholar
  372. Lundgren E, Larsson I, Moirner H, Strannegard 0 (1979) Effects of leukocyte and fibroblast interferon on events in the fibroblast cell cycle. J Gen Virol 42: 589–597Google Scholar
  373. Magee WE, Levine S, Miller OV, Hamilton RD (1968) Inhibition by interferon of the uncoating of vaccinia virus. Virology 35: 505–511PubMedGoogle Scholar
  374. Magee WE, Talcott MJ, Strau SX, Vriend CY (1976) A comparison of negatively and positively charged lysosomes containing entrapped pIC for interferon induction in mice. Biochim Biophys Acta 451: 610–621PubMedGoogle Scholar
  375. Maheshwari RK, Friedman RM (1980) Effect of interferon treatment on vesicular stomatitis virus (VSV): release of unusual particles with low infectivity. Virology 101: 399–407PubMedGoogle Scholar
  376. Maheshwari RK, Banerjee DK, Waechter CJ, Olden K, Friedman RM (1980) Interferon treatment inhibits glycosylation of a viral protein. Nature 287: 454–456PubMedGoogle Scholar
  377. Manders EK, Tilles JG, Huang AS (1972) Interferon-mediated inhibition of virion-directed transcription. Virology 49: 573–581PubMedGoogle Scholar
  378. Mantei N, Schwarzstein M, Streuli M, Panem S, Nagata S, Weissmann C (1980) The nu-cleotide sequence of a cloned human leukocyte interferon cDNA. Gene 10: 1–10PubMedGoogle Scholar
  379. Marcus PI, Sekellick MJ (1977) Defective interfering particles with covalently linked (±) RNA induced interferon. Nature 226: 815–818Google Scholar
  380. Marcus PI, Engelhardt DL, Hunt JM, Sekellick MJ (1971) Interferon action: inhibition of vesicular stomatitis virus RNA synthesis induced by virion-bound polymerase. Science 174: 593–598PubMedGoogle Scholar
  381. Martin EM, Sonnabend JA (1967) Ribonucleic acid synthesis of double-stranded arbovirus ribonucleic acid. J Virol 1: 97–109PubMedGoogle Scholar
  382. Matarese GP, Rossi GB (1977) Effect of interferon on growth and division cycle of Friend erythroleukemic murine cells in vitro. J Cell Biol 75: 344–354PubMedGoogle Scholar
  383. Matsuno T, Shirasawa N, Kohno S (1976) Interferon suppresses glutamine synthetase induction in chick embryonic neural retina. Biochem Biophys Res Commun 70: 310–314PubMedGoogle Scholar
  384. Matsuyama M (1979) Action of interferon on cell membrane of mouse lymphocytes. Exp Cell Res 124: 253–259PubMedGoogle Scholar
  385. Mayhew E, Papahadjopoulos D, O’Malley JA, Carter WA, Vail WJ (1977) Cellular uptake and protection against virus infection by poly IC entrapped within phospholipid vesicles. Mol Pharmacol 13: 488–495PubMedGoogle Scholar
  386. McAuslan BR (1963) The induction and repression of thymidine kinase in the poxvirus-infected HeLa cell. Virology 21: 383–389PubMedGoogle Scholar
  387. McKimm J, Rapp F (1977 a) Variation in ability of measles virus plaque progeny to induce interferon. Proc Natl Acad Sci USA 74:3056–3061PubMedGoogle Scholar
  388. McKimm J, Rapp F (1977 b) Inability of measles virus temperature sensitive mutants to induce interferon. Virology 76:409–421PubMedGoogle Scholar
  389. McNeill TA, Fleming ZWA, McCance DJ (1972) Interferon and hemopoietic colony inhibitor responses to poly I • poly C in rabbits and hamsters. Immunology 22: 711–721PubMedGoogle Scholar
  390. Meager A, Graves HE, Bradshaw TK (1978) Stimulation of interferon yields from cultured human cells by calcium salts. FEBS Letter 87: 303–307Google Scholar
  391. Meager A, Graves HE, Walker JR, Burke DC, Swallow DM, Westerveld A (1979b) Somatic cell genetics of human interferon production in human-rodent cell hybrids. J Gen Virol 45: 309–321PubMedGoogle Scholar
  392. Meldolesi MF, Friedman RM, Kohn LD (1977) An interferon-induced increase in cyclic AMP levels precedes the establishment of the antiviral state. Biochim Biophys Res Commun 70: 239–246Google Scholar
  393. Mellstedt H, Ahre A, Bjorkholm M, Holm G, Johansson B, Strander H (1979) Interferon therapy in myelomatosis. Lancet 1: 245–247PubMedGoogle Scholar
  394. Merigan TC (1967) Induction of circulating interferon by synthetic anionic polymers of known composition. Nature (Lond) 214: 416–417Google Scholar
  395. Merigan TC, Reed SE, Hall TS, Tyrrell DAJ (1973) Inhibition of respiratory virus infection by locally applied interferon. Lancet 1 (803): 563–567PubMedGoogle Scholar
  396. Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordan GW, Fried RP (1978 a) Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med 298:981–987PubMedGoogle Scholar
  397. Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg S (1978 b) Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. New Engl J Med 299:1449–1453 PubMedGoogle Scholar
  398. Metz DH (1975) Interferon and interferon inducers. Adv in Drug Res 10: 101–156Google Scholar
  399. Metz DH, Esteban RM (1972) Interferon inhibits viral protein synthesis in L cells infected with vaccinia virus. Nature 238: 385–388PubMedGoogle Scholar
  400. Metz DH, Levin MJ, Oxman MN (1976) Mechanism of interferon action: further evidence for transcription as a primary site of action in simian virus 40 infection. J Gen Virol 32: 227–240PubMedGoogle Scholar
  401. Metz DH, Oxman MN, Levin MJ (1977) Interferon inhibits the in vitro accumulation of virus specific RNA in nuclei isolated from SV40 infected cells. Biochem Biophys Res Commun 75: 172–178PubMedGoogle Scholar
  402. Miner N, Ray WJ Jr, Simon EM (1966) Effect of interferon on the production and action of viral RNA polymerase. Biochem Biophys Res Commun 24: 261–268Google Scholar
  403. Mizrahi A, O’Malley JA, Carter WA, Takatsuki A, Tamura G, Sulkowski E (1978) Glycosylation of interferons. Effects of tunicamycin on human immune interferon. J Biol Chem 253: 7612–7615PubMedGoogle Scholar
  404. Moehring TJ, Moehring JM, Stinebring WR (1971 a) Response of interferon treated cells to diphtheria toxin. Infect Immun 4:747–752Google Scholar
  405. Moehring JM, Stinebring WR, Merchant DJ (1971 b) Survey of interferon production and sensitivity of human cell lines. Appl Microbiol 22:102–105Google Scholar
  406. Mogensen KE, Pyhala L, Torma E, Cantell K (1974) No evidence for carbohydrate moiety affecting the clearance of circulating human leukocyte interferon in rabbits. Acta Pathol Microbiol Scand B82: 305–310Google Scholar
  407. Montagnier L, Collandre M, De Maeyer-Guignard J, De Maeyer E (1974) Two forms of mouse interferon messenger RNA. Biochem Biophys Res Commun 59: 1031–1038PubMedGoogle Scholar
  408. Morser J, Kabayo JP, Hutchinson DW (1978) Differences in sialic acid content of human interferons. J Gen Virol 41: 175–178PubMedGoogle Scholar
  409. Morser J, Flint J, Meager A, Graves H, Baker PN, Colman A, Burke DC (1979) Characterization of interferon messenger RNA from human lymphoblastoid cells. J Gen Virol 44: 231–234PubMedGoogle Scholar
  410. Mozes LW, Vilcek J (1974) Interferon induction in rabbit cells irradiated with U.V. light. J Virology 13: 646–651PubMedGoogle Scholar
  411. Muthrukrishnan S, Moss B, Cooper JA, Maxell ES (1978) Influence of 5’ terminal structure on the initiation of translation of vaccinia virus mRNA. J Biol Chem 253: 1710–1715Google Scholar
  412. Nagano Y (1975) Virus-inhibiting factor. University of Tokyo Press, Tokyo, pp 1–260Google Scholar
  413. Nagano Y Kojima Y (1954) Pouvoir immunisant de virus vaccinal inactive par des rayo ultraviolets. C.R. Soc Biol (Paris) 148: 1700–1702Google Scholar
  414. Nagano Y, Kojima Y (1958) Inhibition de l’infection vaccinale par le virus homologue. C.R. Seances Soc Biol Filiales 154: 1627–1630Google Scholar
  415. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Escödi J, Boll W, Cantell K, Weissmann C (1980) Synthesis in E. Coli of a polypeptide with human leukocyte interferon activity. Nature 284: 316–320PubMedGoogle Scholar
  416. Nebert DW, Friedman RM (1973) Stimulation of aryl hydrocarbon hydroxylase induction in cell cultures by interferon. J Virol 11: 193–197PubMedGoogle Scholar
  417. Nilson TW, Baglioni C (1979) Mechanism for discrimination between viral and host mRNA in interferon treated cells. Proc Natl Acad Sci USA 76: 2600–2604Google Scholar
  418. Olsen GA, Kern ER, Glasgow LA, Overall JC Jr (1976) Effect of treatment with exogenous interferon Poly I Poly C, or poly I • poly C–poly-lysine complex on EMC virus infections in mice. Antimicrob Agents Chemother 10: 668–679PubMedGoogle Scholar
  419. Olsen GA, Kern ER, Overall JC, Glasgow LA (1978) Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice. J Infect Dis 137: 428–436PubMedGoogle Scholar
  420. O’Malley JA, Leong SS, Horoszewicz JS, Carter WA (1979) Polyinosinic acid-polycytidylic acid and its mismatchend analogues: differential effects on human cell fusion. Molec Pharmacol 15: 165–173Google Scholar
  421. O’Reilly RJ, Everson LK, Emodi G, Hansen J, Smithwick EM, Grimes E, Pahwa S, Pahwa R, Schwartz S, Armstrong D, Siegel FP, Gupta S, Dupont B, Good RA (1976) Effect of exogenous interferon in cytomegalovirus infections complicating bone marrow transplantation. Clin Immunol Immunopathol 6: 51–61PubMedGoogle Scholar
  422. Orlova TG, Georgadze II, Kognovitskaya AL, Soloviev VD (1974) Formation of messenger RNA for interferon in cells treated with various viruses and poly I poly C. Vopr Virusol (4):431–435Google Scholar
  423. Oxman MN (1977) Interferon, tumors and tumor viruses. In: Finter NB (ed) Interferons and interferon inducers, North-Holland Publ Co, Amsterdam, pp 391–480Google Scholar
  424. Oxman MN, Levin MJ (1971) Interferon and transcription of early virus-specific RNA in cells infected with simian virus 40. Proc Natl Acad Sci USA 68: 299–302PubMedGoogle Scholar
  425. Oxman MN, Baron S, Black PH, Takemoto KK, Habel K, Rowe WP (1967) The effect of interferon on SV40 T-antigen production in SV40-transformed cells. Virology 32: 122–127PubMedGoogle Scholar
  426. Pang RHL, Hayes TG, Vilcek J Isolation of Le interferon mRNA from human fibroblasts. Proc Natl Acad Sci USA, to be publishedGoogle Scholar
  427. Paucker K, Cantell K, Henle W (1962) Quantitative studies on viral interference in suspen- ded L cells. V. Persistence of protection on growing cultures. Virology 21: 22–29Google Scholar
  428. Pazin GJ, Armstrong JA, Lam MT, Tarr GC, Jannetta PJ, Ho M (1979) Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. New Engl J med 301: 225–230PubMedGoogle Scholar
  429. Pestka S, McInnes J, Havell EA, Viléek J (1975) Cell-free synthesis of human interferon. Proc Natl Acad Sci USA 72: 3898–3906PubMedGoogle Scholar
  430. Pfeffer LM, Landsberger FR, Tamm I (1981 a) ß-interferon-induced time dependant changes in the plasma membrane lipid bilayer of cultured cells. J Ifn Res 1:615–620Google Scholar
  431. Pfeffer LM, Murphy JS, Tamm I (1979) Interferon effects on the growth and division of human fibroblasts. Exp Cell Res 121: 111–120PubMedGoogle Scholar
  432. Pfeffer LM, Wang E, Landsberger FL, Tamm I (1981 b) Assays to measure plasma membrane and cytoskeletal changes in interferon-treated cells. Methods in enzymology 79:461–413PubMedGoogle Scholar
  433. Pfeffer LM, Wang E, Tamm I (1980 a) Interferon effects on microfilament organization, cellular fibronectin distribution, and cell motility in human fibroblasts. J Cell Biol 85:9–17PubMedGoogle Scholar
  434. Pfeffer LM, Wang E, Tamm I (1980 b) Interferon inhibits redistribution of cell surface components. J Exp Med 152:469–474PubMedGoogle Scholar
  435. Pfeffer LM, Wang E, Fried J, Murphy JS, Tamm I (1982) Interferon as a modulator of fibroblast poliferation and growth. In: Padilla GS, McCarthy KS Jr. (eds) Genetic Expression in the Cell Cycle. Vol II. Academic Press NY, pp 289–314Google Scholar
  436. Pickering LA, Sarkar FH, Stewart WE II (1980) Spontaneous production of human inter-ferons. Abst Ann Meeting Am Soc Microbiol T11, p 237Google Scholar
  437. Pitha PA, Rowe WP, Oxman MN (1976) Effect of interferon on exogenous, endogenous, and chronic murine leukemia virus infection. Virology 70: 324–337PubMedGoogle Scholar
  438. Pitha PA, Staal SP, Bolognesi DP, Denny TP, Rowe WP (1977) Effect of interferon murine leukemia virus infection. II. Synthesis of viral components in exogenous infection. Virology 79: 1–16PubMedGoogle Scholar
  439. Pollard RB, Smith JL, Neal EA, Gregory PB, Merigan TC, Robinson WS (1978) Effect of vidarabine on chronic hepatitis B virus infection. J.A.M.A. 239: 1648–1650PubMedGoogle Scholar
  440. Priestman TJ (1979) Interferon: an anti-cancer agent? Cancer Treat Rev 6: 223–237PubMedGoogle Scholar
  441. Puccetti P, Giampietri A (1978) Immunopharmacology of pyran copolymer. Pharmacological Res Commun 10: 489–501Google Scholar
  442. Purcell RH, Loncon WT, McAuliffe VJ, Palmer AE, Kaplan PM, Gerin JL, Wagner J, Popper H, Lvovsky E, Wong DC, Levy HB (1976) Modification of chronic hepatitis B virus infection in chimpanzees by administration of an interferon inducer. Lancet 2: 757–761PubMedGoogle Scholar
  443. Rabinovitch M, Manejias RE, Russo M, Abbey EF (1977) Increased spreading of macrophages from mice treated with interferon inducers. Cell Immunol 29: 86–93PubMedGoogle Scholar
  444. Radke KL, Colby C, Kates JR, Krider HM, Prescott DM (1974) Establishment and maintenance of the interferon-induced antiviral state: studies in enucleated cells. J Virol 13: 623–645PubMedGoogle Scholar
  445. Raj NBK, Pitha PM (1979) The messenger RNA sequences in superinduced and uninduced human fibroblast cells. Abst Ann Meeting Am Soc Microbiol S80, p 253Google Scholar
  446. Ratner L, Wiegand RG, Farrell PJ, Sen GC, Cabrer B, Lengyel P (1978) Interferon, double stranded RNA and RNA degradation. Fractionation of the endonuclease int system into two macromolecular components, role of a small molecule in nuclease activation. Biochem Biophys Res Commun 81: 947–953PubMedGoogle Scholar
  447. Regelson W (1967) Prevention and treatment of Friend leukemia virus (FLV) infection by interferon-inducing synthetic polyanions. Advanc exp Med Biol 1: 315–332Google Scholar
  448. Reizin FN, Roikhel VM, Chumakov MP (1975) The influence of substances changing the intracellular concentration of cyclic adenosine 3’,5’-monophosphate on interferon synthesis in chick embryo cell culture. Arch Virol. 49: 307–315PubMedGoogle Scholar
  449. Renis HE, Eidson EE (1980) Protection of mice from herpes simplex virus infection by 5-halo, 6-aryl-isocytosines. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious diseases, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, vol II. The American Society for Microbiology, Washington DC, pp 1411–1413Google Scholar
  450. Repik P, Flamand A, Bishop DH (1974) Effect of interferon upon the primary and second- ary transcription of vesicular stomatitis and influenza viruses. J Virol 14: 1169–1178PubMedGoogle Scholar
  451. Revel M (1977) Interferon-induced translation regulation. Tex Rep Biol Med 35: 212–220PubMedGoogle Scholar
  452. Revel M (1979) Molecular mechanisms involved in the antiviral effects of interferon. Interferon 1: 102–157Google Scholar
  453. Revel M, Bash D, Ruddle FH (1976) Antibodies to a cell-surface component coded by human chromosome 21 inhibit action of interferon. Nature 260: 139PubMedGoogle Scholar
  454. Reynolds FH, Pitha PM (1974) The induction of interferon and its messenger RNA in human fibroblasts. Biochem Biophys Res Commun 59: 1023–1030PubMedGoogle Scholar
  455. Reynolds FH Jr, Pitha PM (1975) Molecular weight study of human fibroblast interferon. Biochem Biophys Res Commun 65: 107–114PubMedGoogle Scholar
  456. Reynolds FH Jr, Premkumar E, Pitha PM (1975) Interferon activity produced by translation of human interferon messenger RNA in cell-free ribosomal systems and in Xenopus oocytes. Proc Natl Acad Sci USA 72: 4881–4887PubMedGoogle Scholar
  457. Rhim JS, Heubner RJ (1971) Comparison of the antitumor effect of interferon and interferon inducers. Proc Soc Exp Biol Med 136: 524–529PubMedGoogle Scholar
  458. Roberts WK, Clemens MJ, Kerr IM (1976a) Interferon-induced inhibition of protein synthesis in L-cell extracts: an ATP-dependent step in the activation of an inhibitor by double stranded RNA. Proc Natl Acad Sci USA 70: 3136–3140Google Scholar
  459. Roberts WK, Hovanessian A, Brown RE, Clemens MJ, Kerr I (1976b) Interferon-mediated protein kinase and low molecular weight inhibitor of protein synthesis. Nature 264: 477–480PubMedGoogle Scholar
  460. Rossi GB, Matarese GP, Grapelli C, Belardelli F, Beneditto A (1977) Interferon inhibits di-methyl sulfoxide induced erythroid differentiation of Friend leukemia cells. Nature 267: 50–52PubMedGoogle Scholar
  461. Rozee KR, Katz W, McFarlane ES (1969) Interferon stimulation of methylase activity in L-cells. Can J Microbiol 15: 969–971PubMedGoogle Scholar
  462. Rubinstein M, Rubinstein S, Familletti PC, Gross MS, Miller RS, Waldman AA, Pestka S (1978) Human leukocyte interferon purified to homogeneity. Science 202: 1289–1290PubMedGoogle Scholar
  463. Rubinstein M, Rubinstein S, Familletti PC, Miller RS, Waldman AA, Pestka S (1979) Human leukocyte interferon: production, purification to homogeneity, and initial characterization. Proc Natl Acad Sci USA 76: 640–644PubMedGoogle Scholar
  464. Sagar AD, Pickering LA, Sussman-Berger P, Stewart WE II, Sehgal PB (1981) Heterogeneity of interferon-mRNA species from Sendai virus-induced human lymphoblastoid (Na-malva) cells and Newcastle disease virus-induced murine fibroblastoid ( L) cells. Nucleic Acids Res 9: 149–160PubMedGoogle Scholar
  465. Saito S, Matsuno T, Sudo T, Furuya E, Kohno S (1976) Priming activity of mouse interferon effect on interferon messenger RNA synthesis. Arch Virol 52: 159–163PubMedGoogle Scholar
  466. Salerno RA, Whitmire CE, Garcia IM, Huebner RJ (1972) Chemical carcinogenesis in mice inhibited by interferon. Nature New Biol 239: 31–32PubMedGoogle Scholar
  467. Salvin SB, Youngner JS, Nishio J, Neta R (1975) Tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity. J Natl. Cancer Inst 55: 1233–1235PubMedGoogle Scholar
  468. Sammons ML, Stephen EL, Levy HB, Baron S, Hilmas DE (1977) Interferon induction in cynomolgus and rhesus monkeys after repeated doses of a modified polyriboinosinicpolyribocytidylic acid complex. Antimicrob Agents Chemother 11: 80–83PubMedGoogle Scholar
  469. Samuel CE (1979) Mechanism of interferon action. Kinetics of interferon action in mouse L929 cells: phosphorylation of protein synthesis initiator factor eIF-2 and ribosome associated protein P1. Virology 93: 281–285PubMedGoogle Scholar
  470. Samuel CE, Joklik WK (1974) A protein synthesizing system from interferon-treated cells that discriminates between cellular and viral messenger RNAs. Virology 58: 476–491PubMedGoogle Scholar
  471. Sarma PS, Shiu G, Baron S, Huebner RJ (1969) Inhibitory effect of interferon in murine sarcoma and leukemia virus infection in vitro. Nature 223: 845–846PubMedGoogle Scholar
  472. Schellekens H, Weimar W, Cantell K, Stilz L (1979) Antiviral effect of interferon in vivo may be mediated by the host. Nature 278: 742PubMedGoogle Scholar
  473. Schlesinger RW (1959) Interference between animal viruses. The viruses, vol III. Academic Press, NY, pp 157–194Google Scholar
  474. Schmidt A, Zilberstein A, Shulman L, Federman P, Berissi H, Revel M (1978) Interferon action: isolation of nuclease a translation inhibitor activated by interferon-induced (2’5’) oligoisoadenylate. FEBS Letter 95: 257–264Google Scholar
  475. Schmidt A, Chernajovsky V, Shulman L, Federman P, Berissi H, Revel M (1979) An interferon-induced phosphodiesterase degrading (2’-5’)oligoadenylate and the C-C-A terminus of tRNA. Proc Natl Acad Sci USA 76: 4788–4792PubMedGoogle Scholar
  476. Schonne E, Billiau A, Desomer P (1970) The properties of interferon. IV. Isoelectric focusing of rabbit interferon (NDV-RK13). In: Symp Series Immunbiol 14. Karger, Basel, p 61Google Scholar
  477. Schroeder EW, Chou IN, Jaken S, Black P (1978) Interferon inhibits the release of plasminogen activator from SV 3T3 cells. Nature 276: 828–829Google Scholar
  478. Schultz RM, Chirigos MA (1979) Selective neutralization by antiinterferon globulin of macrophage activation by L-cell interferon, Burcella abortus ether extract, Salmonella typhimurium lipopolysaccharide, and polyanions. Cellular Immunology 48: 52–58PubMedGoogle Scholar
  479. Schultz RM, Papamatheakis JD, Chirigos MA (1977) Interferon: an inducer of macrophage activation by polyanions. Science 197: 674–676PubMedGoogle Scholar
  480. Schultz RM, Chirigos MA, Pavlidis NA, Youngner JS (1978) Macrophage activation and antitumor activity of a Brucella abortus ether extract, Bru-Pel. Cancer Treatment Reports 62: 1937–1941PubMedGoogle Scholar
  481. Scientific Committee on Interferon (1962) Effect of interferon on vaccination in volunteers. Lancet 1: 873–875Google Scholar
  482. Scott GM, Butler JK, Cartwright T, Richards BM, Kingham JG, Wright R, Tyrrell DAJ (1977) Interferon skin reactivity and pyrexial reactions. Lancet 2: 402–403PubMedGoogle Scholar
  483. Scott GM, Cartwright T, Ledu G, Dicker D (1978) Effect of human fibroblast interferon on vaccination in volunteers. J Biol Stand 6: 73–76PubMedGoogle Scholar
  484. Segal S, Khoury G (1979) Differentiation as a requirement for simian virus 40 gene ex- pression in F-9 embryonal carcinoma cells. Proc Natl Acad Sci USA 76: 5611–5615PubMedGoogle Scholar
  485. Segal S, Levine AJ, Khoury G (1979) Evidence for non-spliced SV40 RNA in undifferentiated murine teratocarcinoma stem cells. Nature 280: 335–338PubMedGoogle Scholar
  486. Sehgal PB (1977) Regulation of gene expression in human cells: RNA synthesis and interferon production. PhD dissertation, The Rockefeller UniversityGoogle Scholar
  487. Sehgal PB (1981) Regulation of the stability of human ß interferon mRNA: anchorage independence of the shutoff mechanism. Virology 112: 738–745PubMedGoogle Scholar
  488. Sehgal PB, Gupta SL (1980) Regulation of the stability of poly(I) • poly(C)-induced human fibroblast interferon mRNA: selective inactivation of interferon mRNA and lack of involvement of 2’,5’-oligo(A) synthetase activation during the shutoff of interferon production. Proc Natl Acad Sci USA 77: 3489–3493PubMedGoogle Scholar
  489. Sehgal PB, Sagar ADS (1980) Heterogeneity of poly(I) • poly(C)-induced human fibroblast interferon mRNA species. Nature, to be published 287: 95–97Google Scholar
  490. Sehgal PB, Tamm I (1976) Evaluation of messenger RNA competition in shutoff of human interferon production. Proc Natl Acad Sci USA 73: 1621–1625PubMedGoogle Scholar
  491. Sehgal PB, Tamm I (1978) Halogenated benzimidazole ribosides. Novel inhibitors of RNA synthesis. Biochem Pharmacol 27: 2475–2485PubMedGoogle Scholar
  492. Sehgal PB, Tamm I (1979) Two mechanisms contribute to the superinduction of poly(I) -poly(C)-induced human fibroblast interferon production. Virology 92: 240–244PubMedGoogle Scholar
  493. Sehgal PB, Tamm I ( 1980 a) Antiviral agents: determination of activity. In: Lorian V (ed) Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, pp 573–591Google Scholar
  494. Sehgal PB, Tamm I (1980 b) The transcription unit for poly(I) poly(C)-induced human fibroblast interferon messenger RNA. Virology 102:245–249Google Scholar
  495. Sehgal PB, Tamm I, Vilcek J (1975a) Human interferon production: superinduction by 5,6dichloro-l-ß-D-ribofuranosylbenzimidazole. Science 190: 282–285PubMedGoogle Scholar
  496. Sehgal PB, Tamm I, Vilcek J (1975b) Enhancement of human interferon production by neutral red and chloroquine: analysis of inhibition of protein degradation and macromolecular synthesis. J Exp Med 142: 1283–1290PubMedGoogle Scholar
  497. Sehgal PB, Tamm I, Vilcek J (1976a) On the mechanism of enhancement of human interferon production by actinomycin D and cycloheximide. Virology 70: 256–265PubMedGoogle Scholar
  498. Sehgal PB, Tamm I, Vilcek J (1976b) Regulation of human interferon production: I. Super- induction by 5,6-dichloro-1-D-ribofuranosylbenzimidazole. Virology 70: 532–540PubMedGoogle Scholar
  499. Sehgal PB, Tamm I, Vilcek J (1976c) Regulation of human interferon production. II. Inhibition of interferon messenger RNA synthesis by 5,6-dichloro-1-ß-D-ribofuranosylbenzimidazole. Virology 70: 542–544PubMedGoogle Scholar
  500. Sehgal PB, Darnell JE Jr, Tamm I (1976d) The inhibition by DRB (5,6-dichloro-l-ß-Dribofuranosylbenzimidazole) of hnRNA and mRNA production in HeLa cells. Cell 9: 473–480PubMedGoogle Scholar
  501. Sehgal PB, Dobberstein B, Tamm I (1977) Interferon messenger RNA content of human fibroblasts during induction, shutoff, and superinduction of interferon production. Proc Natl Acad Sci USA 74: 3409–3413PubMedGoogle Scholar
  502. Sehgal PB, Lyles DS, Tamm I (1978a) Superinduction of human fibroblast interferon production: further evidence for increased stability of interferon mRNA. Virology 89: 186–198PubMedGoogle Scholar
  503. Sehgal PB, Soreq H, Tamm I (1978b) Does 3’-terminal poly(A) stabilize human fibroblast interferon mRNA in oocytes of Xenopus laevis? Proc Natl Acad Sci USA 75: 5030–5033Google Scholar
  504. Sen GC, Gupta SL, Brown GE, Lebleu B, Rebello MA, Lengyel P (1976a) Interferon treatment of Ehrlich ascites tumor cells: effects on exogenous mRNA translation of tRNA inactivation in the cell extract. J Virol 17: 191–203Google Scholar
  505. Sen GC, Lebleu B, Brown GE, Kawakita M, Slattery E, Lengyel P (1976b) Interferon, double-stranded RNA and mRNA degradation. Nature 264: 370–373PubMedGoogle Scholar
  506. Sen GC, Desrosiers R, Ratner L, Shaila S, Brown GE, Lebleu B, Slattery E, Kawaita M, Cabrer B, Taira H, Lengyel P (1977a): Messenger RNA methylation, translation and degradation on extracts of interferon-treated cells. Tex Rep Biol Med 35: 221–229PubMedGoogle Scholar
  507. Sen GC, Shaila S, Lebleu B, Brown GE, Desrosier RC, Lengyel P (1977b) Impairment of reovirus mRNA methylation in extracts of interferon-treated Ehrlich ascites tumor cells: further characteristics of the phenomenon. J Virol 21: 69–83PubMedGoogle Scholar
  508. Sen GC, Taira H, Lengyel P (1978) Characteristics of a double-stranded RNA-activated protein kinase system partially purified from interferon-treated Ehrlich ascites tumor cells. J Biol Chem 253: 5915–5921PubMedGoogle Scholar
  509. Senussi OA, Cartwright T, Thompson P (1979) Resolution of human fibroblast interferon into two distinct classes by thiol exchange chromatography. Arch Virol 62: 323–331PubMedGoogle Scholar
  510. Shaila S, Lebleu B, Brown GE, Sen GC, Lengyel P (1977) Characteristics of extracts from interferon-treated HeLa cells, presence of a protein kinase and endoribonuclease activated by double-stranded RNA and of an inhibitor of mRNA methylation. J Gen Virol 37: 535–546Google Scholar
  511. Siegel BV (1975) Enhancement of interferon production by poly(rI) • poly(rC) in mouse cell cultures by ascorbic acid. Nature 254: 531–532PubMedGoogle Scholar
  512. Simli M, Deferra F, Baglioni C (1980) Inhibition of RNA and protein synthesis in interferon treated HeLa cells infected with vesicular stomatitis virus. J Gen Virol 47: 373–384Google Scholar
  513. Sipe JD, Demaeyer-Guignard J, Fauconnier B Demaeyer E (1973) Purification of mouse interferon by affinity chromatography on a solid-phase immunoadsorbent. Proc Natl Acad Sci USA 70: 1037–1040PubMedGoogle Scholar
  514. Skurkovich SV, Kalinina IA, Eremkina EI, Bulycheva TA (1976) Increased sensitivity of leukemia cells incubated in interferon to the action of immune serum. Byull eksp Biol Med 12: 1459–1461Google Scholar
  515. Slate DL, Ruddle FH (1979) Fibroblast interferon in man is coded by two loci on separate chromosomes. Cell 16: 171–180PubMedGoogle Scholar
  516. Slate DL, Shulman L, Lawrence JB, Revel M, Ruddle FH (1978) Presence of human chromosome 21 alone is sufficient for hybrid cell sensitivity of human interferon. J Virol 25: 319–325PubMedGoogle Scholar
  517. Slattery E, Ghosh N, Samanta H, Lengyel P (1979) Interferon, double-stranded RNA, and RNA degradation activation of an endonuclease by (2’-5’)A,,. Proc Natl Acad Sci USA 76: 4778–4782PubMedGoogle Scholar
  518. Sokawa Y, Watanabe Y, Kawade Y (1977) Suppressive effect of interferon on the transition from quiescent to a growing state in 3T3 cells. Nature 268: 236–238PubMedGoogle Scholar
  519. Solov’ev VD (1969) The results of controlled observation on the prophylaxis of influenza with interferon. Bull W.H.O. 41: 683–688PubMedGoogle Scholar
  520. Soloviev VD, Mentkevich LM (1965) The effect of colchicine on viral interference and interferon formation. Acta Virol 9: 308–312Google Scholar
  521. Sonnenfeld G, Mandel AD, Merrigan TC (1977) The immunosuppressive effect of type II mouse interferon preparations on antibody production. Cell Immunol 34: 193–206PubMedGoogle Scholar
  522. Soreq H, Sagar AD, Sehgal PB (1981) Translational activity and functional stability of human fibroblast ßl and ß2 interferon mRNA species lacking 3’-terminal RNA sequences. Proc Natl Acad Sci USA 78: 1741–1745PubMedGoogle Scholar
  523. Stark GR, Dower WJ, Schimke RT, Brown RE, Kerr IM (1979) pppA2’,5’-A2’p5’A synthetase: convenient assay, species and tissue distribution and variation upon withdrawal of oestrogen from chick oviducts. Nature 278:471–473Google Scholar
  524. Stephen EL, Hilmas DE, Mangiafico JA, Levy HB (1977a) Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys. Science 197: 1289–1290PubMedGoogle Scholar
  525. Stephen EL, Sammons ML, Pannier WL, Baron S, Spertzel RO, Levy HB (1977b) Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys ( Macaca mulatta ). J Infect Dis 136: 122–126PubMedGoogle Scholar
  526. Stephen EL, Hilmas DE, Levy HB, Spertzel RO (1979) Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J Infect Dis 139: 267–272PubMedGoogle Scholar
  527. Stern C (1960) Principles of human genetics. 2nd Edition. WH Freeman and Co, San Francisco, LondonGoogle Scholar
  528. Stewart WE II (1974) Distinct molecular species of interferons. Virology 61: 80–86PubMedGoogle Scholar
  529. Stewart WE II (1979) The interferon system. Springer-Verlag, Wien New York, 421 pagesGoogle Scholar
  530. Stewart WE II, Desmyter J (1975) Molecular heterogeneity of human leukocyte interferon: two populations differing in molecular weights, requirements for renaturation and cross-species antiviral activity. Virology 67: 68–78PubMedGoogle Scholar
  531. Stewart WE II, Havell EA (1980) Characterization of a subspecies of mouse interferon cross-reactive on human cells and antigenically related to human leukocyte interferon. Virology 101: 315–318PubMedGoogle Scholar
  532. Stewart WE II, Sulkin SE (1966) Interferon production in hamsters experimentally infected with rabies virus. Proc Soc Exp Biol Med 123: 650–653PubMedGoogle Scholar
  533. Stewart WE II, Gosser LB, Lockard RZ Jr (1971) Priming• a non-antiviral function of interferon. J Virol 7: 792–801PubMedGoogle Scholar
  534. Stewart WE II, Declercq E, Desomer P (1973) Specificity of interferon-induced enhance- ment of toxicity for double-stranded ribonucleic acids. J Gen Virol 18: 237–246PubMedGoogle Scholar
  535. Stewart WE II, Gresser I, Tovey MG, Bandu MT, Legoff S (1976) Identification of the cell-multiplication inhibitory factors in interferon preparations as interferon. Nature 262: 300–303PubMedGoogle Scholar
  536. Stewart WE II, Lin LS, Wiranowska-Stewart M, Cantell K (1977) Elimination of size and charge heterogeneities of human leukocyte interferons by chemical cleavage. Proc Natl Acad Sci USA 74: 4200–4204PubMedGoogle Scholar
  537. Stewart WE II, Chudzio T, Lin LS, Wiranowska-Stewart M (1978) Interferoids: In vitro and in vivo conversion of native interferons to lower molecular weight forms. Proc Natl Acad Sci USA 75: 4814–4818PubMedGoogle Scholar
  538. Stewart WE II, Sarkar FH, Taira H, Hall A, Nagata S, Weissmann C (1980) Comparisons of several biological and physicochemical properties of human leukocyte interferons produced by human leukocytes and by E. coli. Gene 11: 181–186Google Scholar
  539. Strander H (1977) Interferons: anti-neoplastic drugs? Blut 35: 277–288PubMedGoogle Scholar
  540. Strander H, Cantell K (1966) Production of interferon by human leukocytes in vitro. Ann Med Exp Biol Fenn 44: 265–273PubMedGoogle Scholar
  541. Strander H, Cantell K (1974) Studies on antiviral and antitumor effects of human leukocyte interferon in vitro and in vivo. In: Waymouth C (ed) The production and use of interferon for the treatment and prevention of human virus infection. The Tissue Culture Association, Rockville, Md, pp 49–56Google Scholar
  542. Strander H, Cantell K, Carlstrom G, Jakobsson PA (1973) Clinical and laboratory investigations on man; systemic administration of potent interferon to man. J Natl Cancer Inst 51: 733–739PubMedGoogle Scholar
  543. Strander H, Mogensen KE, Cantell K (1974) Production of human lymphoblastoid interferon. J Clin Microbiol 1: 116–117Google Scholar
  544. Strander H, Cantell K, Carlstrom G, Ingimarsson S, Jakobsson P, Nilsonnne U (1976) Acute infections in interferon-treated patients with osteosarcoma: preliminary report of a comparison study. J Infect Dis [Suppl] 133: A245 - A248Google Scholar
  545. Strauchen JA, Young NA, Friedman RM (1977) Interferon-mediated inhibition of mouse mammary tumor virus expression in cultured cells. Virology 82: 232–236PubMedGoogle Scholar
  546. Stringfellow DA, Glasgow LA (1972a) Hyporeactivity of interferon: potential limitation to therapeutic use of interferon-inducing agents. Infect Immun 6: 743–751PubMedGoogle Scholar
  547. Stringfellow DA, Glasgow LA (1972b) Tilorone hydrochloride: an oral interferon-inducing agent. Antimicrob Agents Chemother 2: 73–85PubMedGoogle Scholar
  548. Stringfellow DA, Weed SD, Underwood GE (1979) Antiviral and interferon-inducing prop- erties of 1,5-diamio anthraquinones. Antimicrob Agents Chemother 15: 111–118PubMedGoogle Scholar
  549. Stringfellow DA, Vanderberg HC, Weed SD (1980) Interferon induction by 5-halo-6-phenyl pyrimidines. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious diseases, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, vol II. The American Society for Microbiology, Washington DC, pp 1406–1408Google Scholar
  550. Stylos WA, Chirigos MA, Lengel CR (1978) Lymphocyte stimulatory effect of an ether-ex- tracted preparation of Brucella abortus. Cancer Treatment Reports 62: 1949–1954PubMedGoogle Scholar
  551. Sulkowski E, Davey MW, Carter WA (1976) Interaction of human interferons with immobilized hydrophobic amino acids and dipeptides. J Biol Chem 251: 5381–5390PubMedGoogle Scholar
  552. Sundmacher R, Neumann-Haefelin D, Manthey KF, Muller O (1976a) Interferon in treatment of dendritic keratitis in humans: a preliminary report. J Infect Dis [Suppl] 133: A160 - A164Google Scholar
  553. Sundmacher R, Neumann-Haefelin D, Cantell K (1976b) Interferon treatment of dendritic keratitis. Lancet 1: 1406–1407PubMedGoogle Scholar
  554. Sundmacher R, Neumann-Haefelin D, Cantell K (1976c) Successful treatment of dendritic keratitis with human leukocyte interferon: a controlled clinical study. Albrecht von Graefes Arch Klin Exp Ophthalmol 201: 39–45PubMedGoogle Scholar
  555. Sundmacher R, Neumann-Haefelin D, Cantell K (1977) Quoted in Cantell K (1979)Google Scholar
  556. Sundmacher R, Cantell K, Haug P, Neumann-Haefelin D (1978a) Role of debridement and interferon in the treatment of dendritic keratitis. Albrecht von Graefes Arch Ophthalmol 207: 77–82Google Scholar
  557. Sundmacher R, Neumann-Haefelin D, Cantell K (1978b) Prophylaxis of dendritic keratitis with topical human leukocyte interferon in monkeys and patients treated with steroids. Quoted in Dunnick and Galasso (1979)Google Scholar
  558. Sundmacher R, Cantell K, Haug P, Neumann-Haefelin D (1978c) Interferon Prophylaxe von dendritica rezidivien bei lokaler steroid-therapie. Quoted in Dunnick and Galasso (1979)Google Scholar
  559. Sundmacher R, Cantell K, Neumann-Haefelin D (1978d) Combination therapy of dendritic keratitis with trifluorothymidine and interferon. Lancet 2: 687PubMedGoogle Scholar
  560. Sundmacher R, Cantell K, Skoda R, Hallermann C, Neumann-Haefelin D ( 1979 ) Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis. Quoted in Cantell (1979)Google Scholar
  561. Svet-Moldaysky GJ, Chemyakovskaya IY (1967) Interferon and the interaction of allogeneic normal and immune lymphocytes with L cells. Nature 215: 1299–1300Google Scholar
  562. Taggart MT, Loughman BE, Gibbons AJ, Stringfellow DA (1980) Immunomodulatory effects of 2-amino-5-bromo-6-methyl-4-pyrimidinol and its isocytosine analogs. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious diseases, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, vol 11. The American Society for Microbiology, Washington DC, pp 1400–1401Google Scholar
  563. Taira H, Broeze RJ, Jayaram BM, Lengyel P, Hunkapiller MW, Hood LE (1980) Mouse interferons: amino terminal amino acid sequences of various species. Science 207: 528–530PubMedGoogle Scholar
  564. Tamm I, Sehgal PB (1977) A comparative study of the effects of certain halogenated benzimidazole ribosides on RNA synthesis, cell proliferation, and interferon production. J Exp Med 145: 344–356PubMedGoogle Scholar
  565. Tamm I, Sehgal PB (1978) Halobenzimidazole ribosides and RNA synthesis of cells and viruses. Adv Virus Res 22: 187–258PubMedGoogle Scholar
  566. Tamm I, Sehgal PB (1979) New evidence for regulated transcription of mRNA and for regulated translation of interferon mRNA in human cells. In: Engberg J, Klenow H, Leick V (eds) Specific eukaryotic genes, Alfred Benzon Symposium 13, Munksgaard, Copenhagen, pp 424–439Google Scholar
  567. Tamm I, Hand R, Caliguiri LA (1976) Action of dichlorobenzimidazole riboside on RNA synthesis in L-929 and HeLa cells. J Cell Biol 69: 229–240PubMedGoogle Scholar
  568. Tan YH (1976) Chromosome 21 and the growth inhibitory effect of human interferon preparations. Nature 260: 141–142PubMedGoogle Scholar
  569. Tan YH, Berthold W (1977) A mechanism for the induction and regulation of human interferon genetic expression. J Gen Virol 34: 401–412PubMedGoogle Scholar
  570. Tan YH, Greene AE (1976) Subregional localization of the genes governing the human interferon-induced antiviral state in man. J Gen Virol 32: 153–157PubMedGoogle Scholar
  571. Tan YH, Armstrong JA, Ke YM, Ho M (1970) Regulation of cellular interferon production: enhancement by antimetabolites. Proc Natl Acad Sci USA 67: 464–471PubMedGoogle Scholar
  572. Tan YH, Armstrong JA, Ho M (1971) Accentuation of interferon production by metabolic inhibitors and its dependence on protein synthesis. Virology 41: 503–509Google Scholar
  573. Tan YH, Schneider EL, Tishfield J, Epstein CJ, Ruddle FM (1974 a) Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state. Science 186:61–63PubMedGoogle Scholar
  574. Tan YH, Creagan RP, Ruddle FM (1974b) The somatic cell genetics of human interferon: assignment of human interferon loci to chromosomes 2 and 5. Proc Natl Acad Sci USA 71: 2251–2255PubMedGoogle Scholar
  575. Tan YH, Barakat F, Berthold W, Smith-Johannsen H, Tan C (1979) The isolation and amino acid/sugar composition of human fibroblastoid interferon. J Biol Chem 254: 8067–8073PubMedGoogle Scholar
  576. Tanamoto K-I, Abe C, Homma JY, Kojima Y (1979) Regions of the lipopolysaccharide of Pseudomonas aeruginosa essential for antitumor and interferon-inducing activities. Eur J Biochem 97: 623–629PubMedGoogle Scholar
  577. Taniguchi T, Sakai M, Fuji-Kuriyama Y, Muramatsu M, Kobayashi S, Sudo T (1979) Construction and identification of bacterial plasmid containing the human fibroblast interferon gene sequence. Proc Japan Acad, Ser B 55: 464–489Google Scholar
  578. Taniguchi T, Ohno S, Fuji-Kuriyama Y, Muramatsu Y (1980a) The nucleotide sequence of human fibroblast interferon DNA. Gene 10: 11–15PubMedGoogle Scholar
  579. Taniguchi T, Mantei N, Schwarzstein M, Nagata S, Muramatsu M, Weissmann C (1980b) Human leukocyte and fibroblast interferons are structurally related. Nature 285:547–549PubMedGoogle Scholar
  580. Taniguchi T, Guarente L, Roberts TM, Kimelman D, Douhan J III, Ptashne M (1980c) Expression of the human fibroblast interferon gene in Escherichia coli. Proc Natl Acad Sci USA 77: 5230–5233PubMedGoogle Scholar
  581. Tarodi B, Metz DH, Douglas A, Russell WK (1977) A study of events in chick cells infected with human adenovirus type 5 and their relationship to the induction of interferon. J Gen Virol 36: 425–436PubMedGoogle Scholar
  582. Taylor J (1964) Inhibition of interferon action by actinomycin. Biochem Biophys Res Commun 14: 447–453PubMedGoogle Scholar
  583. Taylor JL, Schoenherr CK, Grossberg SE (1980a) High-yield interferon induction by 10carboxymethyl-9-acridanone in mice and hamsters. Antimicrob Agents and Chemo 18: 20–26Google Scholar
  584. Taylor JL, Schoenherr C, Grossberg SE (1980b) Protection against Japanese encephalitis in mice and hamsters by treatment with carboxymethyl-acridanone, a potent interferon inducer. J Infect Dis 142: 394–399PubMedGoogle Scholar
  585. Thacore HR (1978) Effect of interferon on transcription and translation of vesicular stomatis virus in human and simian cell cultures. J Gen Virol 41: 421–426PubMedGoogle Scholar
  586. Thang MN, Thang DC, DeMaeyer E, Montagnier L (1975) Biosynthesis of mouse interferon by translation of its messenger RNA in a cell-free system. Proc Natl Acad Sci USA 72: 3975–3979PubMedGoogle Scholar
  587. Tomkins GM, Levinson BB, Baxter JD, Dethlefsen L (1972) Further evidence for post-transcriptional control of inducible tyrosine aminotransferase synthesis in cultured hepatoma cells. Nature New Biol 239: 9–14PubMedGoogle Scholar
  588. Törma ET, Paucker K (1976) Purification and characterization of human leukocyte interferon components. J Biol Chem 251: 4810–4820PubMedGoogle Scholar
  589. Torrence PF, Friedman RM (1979) Are double-stranded RNA-directed inhibition of protein synthesis in interferon-treated cells and interferon induction related phenomena? J Biol Chem 256: 1259–1267Google Scholar
  590. Tovey MG, Begon-Lours J, Gresser I (1974) A method for large-scale production of potent interferon preparations. Proc Soc Exp Biol Med 146: 809–815PubMedGoogle Scholar
  591. Tovey MG, Brouty-Boyé D, Gresser I (1975) Interferon and cell division X. Early effect of interferon on mouse leukemia cells cultured in a chemostat. Proc Natl Acad Sci USA 72: 2265–2269Google Scholar
  592. Tovey MG, Begon-Lours J, Gresser I, Morris AG (1977) Marked enhancement of interferon production in 5-bromodeoxyuridine treated human lymphoblastoid cells. Nature 267: 455–456PubMedGoogle Scholar
  593. Tovey MG, Egly CR, Castagna M (1979) Effect of interferon on concentration of cyclic nucleotides in cultured cells. Proc Natl Acad Sci 76: 3890–3893PubMedGoogle Scholar
  594. Trapman J (1979) A systematic study of interferon production by mouse L-929 cells induced with poly(I) • poly(C) and DEAE-dextran. FEBS Lett 98: 107–110PubMedGoogle Scholar
  595. Tyrrell DAJ (1959) Interferon produced by culures of calf kidney cells. Nature 184:452–453 Tyrrell DAJ, Tamm I (1955) Prevention of virus interference by 2,5-dimethylbenzimidazole. J Immunol 75: 43–49Google Scholar
  596. Vasseff A, Spencer C, Gelehrter TD, Lengyel P (1974) Selectivity of interferon action: hormonal induction of tyrosine aminotransferase in rat hepatoma cells is much less sensitive to interferon than the replication of vesicular stomatitis virus or reovirus. Biochem Biophys Acta 353: 115–120Google Scholar
  597. Vengris VE, Stollar BD, Pitha PM (1975) Interferon externalization by producing cell before induction of antiviral state. Virology 65: 410–417PubMedGoogle Scholar
  598. Vengris VE, Reynolds FH Jr, Hollenberg MD, Pitha PM (1976) Interferon action: role of membrane gangliosides. Virology 72: 486–493PubMedGoogle Scholar
  599. Vennström B, Persson H, Pettersson U, Philipson L (1979) A DRB (5,6-dichloro-ß-D-ribofuranosylbenzimidazole)-resistant adenovirus mRNA. Nuc Acids Res 7: 1405–1418Google Scholar
  600. Vignaux F, Gresser I (1977) Differential effects of interferon on the expression of H-2K,H-2D and 1 a antigens on mouse lymphocytes. J Immunol 118: 721–723PubMedGoogle Scholar
  601. Vilcek J (1962) Studies on an interferon from tick-borne encephalitis virus infected cells. IV. Comparison of IF with interferon from influenza virus-infected cells. Acta Virol 6: 144–160PubMedGoogle Scholar
  602. Vilcek J (1970) Metabolic determinants of the induction of interferon by a double-stranded polynucleotide in rabbit cells. Ann NY Acad Sci 173: 390–403Google Scholar
  603. Viléek J, Ng MH (1971) Post-transcriptional control of interferon synthesis. J Virol 7: 588–594Google Scholar
  604. Vilcek J, Rada B (1962) Studies on an interferon from tick-borne encephalitis virus infected cells. III. Antiviral action of IF. Acta Virol 6: 9–15PubMedGoogle Scholar
  605. Vilcek J, Rossman TC, Varacalli F (1969) Differential effects of Actinomycin D and puromycin on the release of interferon induced by double-stranded RNA. Nature 222: 682–683PubMedGoogle Scholar
  606. Vilcek J, Havell EA, Kohase A (1976) Superinduction of interferon with metabolic inhibitors: possible mechanisms and practical applications. J Infect Disease 133: A22 - A29Google Scholar
  607. Vilcek J, Yamazaki S, Havell EA (1977) Interferon induction by vesicular stomatitis virus and its role in virus replication. Infect Immun 18: 836–867Google Scholar
  608. Virelizier J-L, Gresser I (1978) Role of interferon in the pathogenesis of mice as demonstrated by the use of anti-interferon serum. IV. Protective role in mouse hepatitis virus Type 3 infection of susceptible and resistant strains of mice. J Immunol 120: 1616–1619PubMedGoogle Scholar
  609. Virelizier JL, Allison AC, DeMaeyer E (1977) Production by mixed lymphocyte cultures of a Type II interferon able to protect macrophages against virus infections. Infect Immun 17: 282–296PubMedGoogle Scholar
  610. Waldman RH, Ganguly R (1978) Effect of CP-20,961, an interferon inducer, on upper respiratory tract infections due to rhinovirus Type 21 in volunteers. J Infect Dis 138: 531–535PubMedGoogle Scholar
  611. Weber JM, Stewart RB (1975) Cyclic AMP potentiation of interferon antiviral activity and effect of interferon on cellular cyclic AMP levels. J Gen Virol 28: 363–372PubMedGoogle Scholar
  612. Weed SD, Kramer GD, Stringfellow DA (1980) Antiviral properties of 6-arylpyrimidines. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious diseases, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, vol II. Society for Microbiology, Washington DC, pp 1408–1409Google Scholar
  613. Weimar W, Heijtink RA, Schalm SW, Van Blankenstein M, Schellekens H, Masurel N, Edy VG, Billiau A, De Somer P (1977) Fibroblast interferon in HBsAg-positive chronic active hepatitis. Lancet 2: 1282PubMedGoogle Scholar
  614. Weimar W, Schellekens H, Lameijer LDF, Masurel N, Edy VG, Billiau A, De Somer P (1978 a) Double-blind study of interferon administration in renal transplant recipients. Eur J Clin Invest, Quoted in Dunnick and Galasso (1979)Google Scholar
  615. Weimar W, Heijtink RA, Schalm SW, Schellekens H ( 1978b ) Differential effects of exogenous fibroblast and leukocyte interferon in HBsAg chronic hepatitis [abstract]. Gastroenterology, Quoted in Dunnick and Galasso (1979)Google Scholar
  616. Weimar W, Heijtink RA, Ten Kate FJP, Schalm SW, Masurel N, Schellekens H, Cantell K (1980) Double-blind study of leukocyte interferon administeration in chronic HBsAgpositive hepatitis. Lancet 1: 336–338PubMedGoogle Scholar
  617. Weissenbach J, Zeevi M, Landau T, Revel M (1979) Identification of the translation products of human fibroblast interferon mRNA in reticulocyte lysates. Eur J Biochem 98: 1–8PubMedGoogle Scholar
  618. Weissenbach J, Chernajovsky Y, Zeevi M, Shulman L, Soreq H, Nir U, Wallach D, Perricaudet M, Tiollais P, Revel M (1980) Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci USA 77:7152–7156Google Scholar
  619. Werenne J, Edmonts-Alt X, Bartholeyns J (1980) Interferon regulates cell motility. Ann NY Acad Sci 350: 623–624Google Scholar
  620. Werner GH, Jasmin C, Chermann JC (1976) Effect of ammonium-S-tungsts-2-antimoniate on EMC and VSV infections in mice. J Gen Virol 31: 59–64PubMedGoogle Scholar
  621. Wheelock EF (1965) Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 149: 310–311Google Scholar
  622. Wheelock EF, Larke RPB (1968) Efficacy of interferon in the treatment of mice with established Friend virus leukemia. Proc Soc Exp Biol Med 127: 230–236PubMedGoogle Scholar
  623. Wiebe ME, Joklik WK (1975) The mechanism of inhibition of reovirus replication by interferon. Virology 66: 229–240PubMedGoogle Scholar
  624. Wierenga W, Skulnick HI, Weed SD, Stringfellow DA (1980) Antiviral and interferon induction structure-activity relationship profile of 6-aryl pyrimidenes. In: Nelson JD, Grassi C (eds) Current chemotherapy and infectious diseases, Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, vol II. Society for Microbiology, Washington DC, pp 1402–1404Google Scholar
  625. Wiktor TJ, Fernandes MV, Koprowski H (1964) Cultivation of rabies viruses in human diploid cell strain WI-38. J Immunol 93: 353–360PubMedGoogle Scholar
  626. Williams BRG, Kerr IM (1978) Inhibition of protein synthesis by 2’ 5’ linked adenine oligonucleotides in intact cells. Nature 276: 88–90PubMedGoogle Scholar
  627. Williams BRG, Kerr IM, Gilbert CS, White CN, Ball LA (1978) Synthesis and breakdown of ppp A2’p 5’A 2’p 5’A and transient inhibition of protein synthesis in extracts from interferon-treated and control cell. Eur J Biochem 92: 455–462PubMedGoogle Scholar
  628. Wiranowska-Stewart M, Stewart WE II (1977) The role of human chromosome 21 in sensitivity to interferons. J Gen Virol 37: 629–634Google Scholar
  629. Wiranowska-Stewart M, Chudzio T, Stewart WE II (1977) Repeated superinduction of interferon in human diploid fibroblast cultures. J Gen Virol 37: 351–374Google Scholar
  630. Wiranowska-Stewart M, Lin LS, Braude IA, Stewart WE II (1980) Production, partial purification and characterization of human and murine interferon-type II. Molecular Immunol, 14: 625–633Google Scholar
  631. Wong PKY, Yuen PM, MacLeod R, Chang EH, Myers MW, Friedman RM (1977) The effect of interferon on de novo infection of Moloney murine leukemia virus. Cell 10: 245–252PubMedGoogle Scholar
  632. Yabrov AA (1966) The enhancement of the stability of cells to diptheria toxin under the influence of a latent viral infection. Cytol 8: 767–769Google Scholar
  633. Yagi MJ, King NW Jr, Bekesi JG (1980) Alteration of a mouse mammary tumor virus glycoprotein with interferon treatment. J Virol 34: 225–233PubMedGoogle Scholar
  634. Yakobson E, Prives C, Hartman JR, Winocour E, Revel M (1977) Inhibition of viral protein synthesis in monkey cells treated with interferon late in simian virus 40 lytic cycle. Cell 12: 73–81PubMedGoogle Scholar
  635. Yamaguchi T, Handa K, Shimizu Y, Abo T, Kumagai K (1977) Target cell for interferon production in human leukocytes stimulated by Sendai virus. J Immunol 118: 1931–1946PubMedGoogle Scholar
  636. Yamamoto Y, Kawade Y (1976) Purification of two components of mouse L-cell interferon: electrophoretic demonstration of interferon proteins. J Gen Virol 33: 225–234PubMedGoogle Scholar
  637. Yamamoto Y, Kawade Y (1980) Antigenicity of mouse interferons: distinct antigenicity of the two L-cell interferon species. Virology 103: 80–88PubMedGoogle Scholar
  638. Yamamoto K, Yamaguchi N, Oda K (1975) Mechanism of interferon induced inhibition of early simian virus 40 functions. Virology 68: 58–70PubMedGoogle Scholar
  639. Yaron M, Yaron I, Gurari-Rotman D, Revel M, Lindner HR, Zor U (1977) Stimulation of prostaglandin E production in cultured human fibroblasts by poly I:C and and human interferon. Nature 267: 457–459Google Scholar
  640. Yonehara S, Iwakuna Y, Kawade Y (1980) Rapid purification of mouse L-cell interferon labeled with radioactive amino acid by immune precipitation. Virology 100: 125–129PubMedGoogle Scholar
  641. Yoshida M, Azuma M, Suenaga T, Mizuno F (1978) Regulation of interferon production by dibutyryl cyclic AMP in serum-free human diploid cell cultures. J Gen Virol 39: 303–310PubMedGoogle Scholar
  642. Young CHS, Pringle CR, Follett EAC (1975) Effect of interferon in enucleated cells. J Virol 15: 428–441PubMedGoogle Scholar
  643. Youngner JS (1970) Influence of inhibitors of protein synthesis on interferon formation in mice. II. Comparison of effects of glutarimide antibotics and tenuazonic acid. Virology 40: 335–343PubMedGoogle Scholar
  644. Youngner JS, Feingold DS (1980) Potential for cancer therapy with a Brucella Abortus preparation (BRU-PEL). In: Hersh EM, Chirigos M, Mastrangelo M (eds) Augmenting agents in cancer therapy. Current status and future prospects, vol 16. Raven Press, New York, pp 205–213Google Scholar
  645. Youngner JS, Hallum JV (1968) Interferon production in mice by double-stranded synthetic polynucleotides: induction or release. Virology 35: 177–185PubMedGoogle Scholar
  646. Youngner JS, Stinebring WR (1965) Interferon appearance stimulated by endotoxin, bacteria, or viruses in mice pretreated with E. coli, endotoxin, or infected with Mycobacterium tuberculosis. Nature 208: 456–458PubMedGoogle Scholar
  647. Youngner JS, Stinebring WR, Taube SG (1965) Influence of inhibitors of protein synthesis on interferon formation in mice. Virology 27: 541–564PubMedGoogle Scholar
  648. Youngner JS, Keleti G, Feingold DS (1974) Antiviral activity of an ether-extracted nonviable preparation of Burcella abortus. Infection and Immunity 10: 1202–1206PubMedGoogle Scholar
  649. Zilberstein A, Federman P, Shulman L, Revel M (1976) Specific phosphorylation in vitro of a protein associated with ribosomes of interferon-treated mouse L-cells. FEBS Lett 68: 119–124PubMedGoogle Scholar
  650. Zilberstein A, Kimchi A, Schmidt A, Revel M (1978) Isolation of two interferon induced translational inhibitors: a protein kinase and an oligoisoadenylate sythetase. Proc Natl Acad Sci 75: 4734–4738PubMedGoogle Scholar
  651. Zoon KC, Buckler CE, Bridgen PJ, Gurari-Rotman D (1978) Production of human lymphoblastoid interferon by Namalwa cells. J Clin Microbiol 7: 44–51PubMedGoogle Scholar
  652. Zoon KC, Bridgen PJ, Smith ME (1979 a) Production of human lymphoblastoid interferon by Namalwa cells cultures in serum-free media. J Gen Virol 44:227–229PubMedGoogle Scholar
  653. Zoon KC, Smith ME, Bridgen PJ, Zur Nedden D, Anfinsen CB (1979b) Purification and partial characterization of human lymphoblastoid interferon. Proc Natl Acad Sci USA 76: 5601–5605PubMedGoogle Scholar
  654. Zoon KC, Smith ME, Bridgen PJ, Anfinsen CB, Hunkapiller MW, Hood LE (1980) Amino terminal sequence of the major component of human lymphoblastoid interferon. Science 207: 527–528PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • P. B. Sehgal
  • L. M. Pfeffer
  • I. Tamm

There are no affiliations available

Personalised recommendations